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ABSTRACT OF DISSERTATION 
 
 
 
EPIGENETIC IMPLICATIONS IN INORGANIC ARSENIC-MEDIATED 
CARCINOGENESIS 
 
 Chronic, low dose exposure to inorganic arsenic (iAs) is a public health concern 
throughout the world, contributing to the development of many diseases, including lung 
cancer. Several mechanisms for iAs-mediated carcinogenesis have been proposed, of 
which the production of reactive oxygen species and formation of chromosomal 
aberrations are the most studied. Another equally important, yet less studied mechanism 
is dysregulation of epigenetic marks. “Epigenetics” refers to changes that occur on the 
DNA and chromatin that do not alter base pair identity, but alter compaction, expression, 
and regulation of specific DNA sequences. There are several types of epigenetic marks 
including histone post-translational modifications, DNA methylation, and histone 
variants. Understanding the role of these epigenetic regulators in iAs-mediated 
carcinogenesis is, therefore, important because these aberrant changes influence the 
disease phenotype. Specifically, these epigenetic changes have been implicated in a 
process called the epithelial-to-mesenchymal transition, which allows cancer cells to 
metastasize. First, this study used high-resolution microarray analysis to measure the 
changes in DNA methylation in cells undergoing inorganic arsenic-induced epithelial-to-
mesenchymal transition, and on the reversal of this process, after removal of the 
inorganic arsenic exposure. Inorganic arsenic exposure not only influences DNA 
methylation, but we also identified for the first time that differential expression of 
specific histone H2B variants occurs in iAs-exposed cells. The histone H2B variants, 
which have point amino acid changes compared to the canonical sequence, exhibit 
dysregulated expression patterns that are responding to iAs-induced changes in stem loop 
binding protein (SLBP), which is responsible for regulating histone variant transcripts. 
While the H2B variants have only a few small amino acid changes, some are located at 
histone:DNA interfaces, while others are at histone:histone interfaces. These small amino 
acid changes could cause steric and electrostatic changes which influence nucleosome 
dynamics. Therefore, this study also sought to reveal how histone H2B variants influence 
octamer and nucleosome stability. We found that histone H2B variants confer unique 
stability and dynamic properties to both the histone octamer and the nucleosome. 
     
 
Therefore, histone H2B variants are playing a unique role in chromatin dynamics, both in 
iAs-induced carcinogenesis and normal chromatin functioning. In whole, this study 
identified multiple epigenetic marks that are disrupted by iAs treatment and identified 
how those epigenetic marks may be influencing chromatin compaction to promote the 
epithelial-to-mesenchymal transition. 
 
KEYWORDS: Inorganic Arsenic, DNA Methylation, Histone H2B Variants, Octamer 
Stability, Nucleosome Stability, Stem Loop Binding Protein 
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CHAPTER 1.  BACKGROUND – EPIGENETIC REPROGRAMMING IN 
INORGANIC ARSENIC-MEDIATED GENE EXPRESSION PATTERNS DURING 
CARCINOGENESIS 
 Introduction 
Inorganic arsenite (iAs) is a naturally-occurring toxic metalloid to which humans are 
routinely exposed through the environment. It is widely distributed in the earth’s crust and 
is ubiquitous in soil, water, and air. Humans are chronically exposed to iAs through 
contaminated food and drinking water 1,2. It is estimated that contaminated wells, formed 
from proximity to iAs-rich geological formations, expose 160 million individuals 
worldwide to excessive levels of iAs1 (Figure 1.1). The long-term effects of low-dose iAs 
exposure from contaminated drinking water continue as mining efforts, which release high 
amounts of iAs into the groundwater, persist in many regions of the world1,3,4. While not 
genotoxic, arsenic and iAs compounds are listed as known human carcinogens by the 
National Toxicology Program2. Epidemiological studies demonstrate a strong relationship 
between environmental iAs exposure and an increased cancer incidence. Such exposure 
correlates with an increased risk of lymphatic 5, hematopoietic 6, skin, lung 5-7, digestive 
tract 5, liver 6, urinary tract 6,8,9, and prostate 5,6 cancers. Although the precise mechanisms 
by which iAs causes cancer remain elusive, several mechanisms have been proposed. 
These mechanisms include iAs-induced oxidative stress, inhibition of DNA repair, 
micronuclei formation, chromosomal aberrations, and changes to the epigenome. While 
arsenic is present in the environment in several different forms, inorganic arsenite is known 
to be the most toxic form. This is due to its high solubility in water (compared to organic 
arsenic compounds) and lone electron pair that can participate in chemical bonds (more so 
than arsenate which does not have an electron pair). This review will focus on proposed 
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epigenetic mechanisms that contribute to inorganic arsenic-induced toxicity and 
carcinogenesis. 
 
 Proposed Mechanisms of iAs Mediated Carcinogenesis and Toxicity 
A variety of mechanisms may contribute to the carcinogenicity caused by iAs. One 
mechanism involves the iAs-induced production of reactive oxygen species (ROS). The 
impact of iAs on ROS production is hypothesized to occur in two steps. First, iAs initiates 
production of high ROS levels, which chemically react with DNA. This reaction damages 
the DNA and disrupts its structural integrity, thus contributing to cellular transformation 
and tumor proliferation 10,11. Second, cells react to the increased amounts of ROS by 
overexpressing the antioxidant enzymes superoxide dismutase, catalase, and glutathione, 
which protect cells against apoptosis. The decreased apoptosis and accumulation of 
damaged cells increases carcinogenic potential 10.  
Chromosomal instability and epigenetic modifications may also play roles in the 
carcinogenicity of iAs. At low doses, iAs does not cause DNA base pair mutations; instead, 
it is known to generate double-stranded breaks 12, which result in large-scale chromosomal 
aberrations 13. This iAs-mediated chromosomal instability occurs frequently at 
centromeres, leading to the formation of acentric chromosomes or the fusion of 
centromeres between two chromosomes 14. Fusion of two chromosomes at their 
centromeres can cause improper chromosome segregation, which results in aneuploidy or 
in micronuclei formation 12,15. On the other hand, fusion that occurs at chromosomal ends 
may result in the formation of ring-like structures and/or participate in abnormal sister 
chromatid exchanges 14,16; both of which are deleterious to the cell. While these are large-
13 
 
scale chromosomal rearrangements, iAs also effects changes to chromatin structure at the 
nucleosome level; these changes alter local chromatin conformation that ultimately fine-
tune the iAs-mediated gene expression profile. 
Eukaryotic DNA is packaged in the form of chromatin, which has a basic repeating 
unit, the nucleosome. Each nucleosome consists of 147 DNA base pairs wrapped around 
two molecules each of four canonical histones (histones H2A, H2B, H3, and H4). The tails 
of these histones are subject to a variety of posttranslational modifications (PTMs) 17,18, 
which are dynamically regulated to control the accessibility of chromatin to factors that 
direct gene expression. Histone PTMs, other epigenetic marks (e.g., methylated DNA or 
distinctly-combined histone variants), and microRNAs are collectively known as 
epigenetic regulators. The remainder of this review will focus on the most recent studies 
that investigate the role of iAs exposure in reprogramming these epigenetic marks, and 
how this reprogramming may mediate iAs toxicity.  
 
 DNA Methylation 
DNA methylation (5mC) is one of several epigenetic mechanisms that cells use to 
control gene expression. The effect of DNA methylation on a gene’s expression depends 
on the type of regulatory element at which the methylation occurs. For instance, 
methylation of a promoter is associated with gene repression. On the other hand, 
methylation within the gene body is generally associated with gene expression and splice 
regulation, although the latter processes are poorly understood.  
The results of several studies have implicated aberrant DNA methylation in many 
cancers but our understanding of the impact of iAs on DNA methylation is just emerging 
14 
 
19-21. For instance, Zhao et al. showed that chronic, low-dose exposure of cells to iAs for 
18 weeks caused global hypomethylation. Other studies revealed that iAs exposure to 
human skin led to global hypomethylation of some tissues (leukocytes) and iAs exposure 
in rodent liver instigated hypomethylation 22,23. However, other research indicates that iAs 
exposure leads to hypermethylation at the promoters of specific tumor suppressor genes, 
resulting in their repression 24,25. For example, in iAs-exposed human hepatocytes, 
significant hypermethylation of the promoters for genes involved in DNA repair such as 
ERCC2 and RPA1, and of genes associated with the Wnt pathway like MYC and WNT2B, 
were observed 24. Additionally, significant hypermethylation of the promoters for the 
tumor suppressor p16 26,27, and the DNA repair gene, MLH1 26, were observed in whole 
blood obtained from humans chronically exposed to iAs. Conversely, iAs-induced 
hypomethylation of promoters for genes involved in processes such as endocytosis and 
RNA transport were also observed 24. Interestingly, another study involving chronic 
exposure of a human population to arsenic demonstrated hypomethylation at the promoter 
of the DNA repair gene, ERCC2 28.  
While these findings may at first seem incongruous, it is now clear that, although 
global hypomethylation occurs, modifications at specific genetic loci can also be either 
hypo- or hypermethylated. Furthermore, it is possible that some of these disparities may 
be explained by the use of different model systems, different stages of malignant 
transformation, and different experimental conditions (e.g., the dose of iAs, the duration 
of iAs exposure, and the presence or absence of other carcinogens). For instance, Pilser et 
al suggested that folate can influence iAs-mediated DNA methylation profiles in 
peripheral blood leukocytes taken from Bangladeshi adults 23. Overall, though, these 
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studies suggest that iAs-mediated malignant transformations result from multiple changes 
in DNA methylation patterns, and that these altered patterns can have positive or negative 
effects on the expression of specific genes. One should be cautious when drawing general 
conclusions about observed iAs-induced changes in DNA methylation patterns from any 
one study. Most importantly, profiling of DNA methylation changes should be performed 
together with analyses of the functional consequences of such changes in DNA 
methylation. 
Researchers have proposed several possible mechanisms for iAs-mediated changes 
in DNA methylation. In humans, DNA methylation at cytosine residues is initiated by the 
de novo DNA methyltransferase 3 (DNMT3A and B) and maintained by DNA 
methyltransferase 1 (DNMT1) 29. Following low dose iAs exposure, the expression of the 
DNMTs is reduced, which results in less methylation at target sites 30-32. Because DNMTs 
also participate in DNA repair, inactivation and/or reduction in the expression levels of 
DNA methyltransferases will also impede DNA repair efficiency 25,31,33,34. Another 
possible explanation for iAs-mediated alterations in DNA methylation involves the 
depletion of methyl groups. When cells metabolize arsenic, the arsenic methyltransferase, 
AS3MT, transfers a methyl group from S-adenosylmethionine (SAM) to the arsenite 24, 
depleting the available methyl groups needed by the DNMTs for DNA methylation 31. This 
competition for methyl groups affects DNA methylation supported by DNMTs, but also 
the histone methyltransferases. As the name implies, these enzymes methylate histones 
and, likewise, are important components of epigenetic regulation. Interestingly, there is 
interplay between DNA methylation and histone modification; thus, an imbalance in one 
epigenetic mark could also trigger other epigenetic changes at specific gene regulatory 
16 
 
regions. Finally, iAs-mediated changes to DNA methylation may also occur through 
altered DNA demethylase activity. TET1 and TET2 are the DNA demethylase enzymes 
responsible for oxidizing 5mC to 5-hydroxymethylcytosine (5hmC). Recent studies 
revealed that chronic iAs treatment leads to an upregulation in TET expression due to 
enhanced binding of the CTCF transcription factor at the TET promoter. This finding is 
complemented by the finding that chronic iAs treatment leads to an increase in global 
5hmC levels. It is likely that iAs-induced changes to DNA methylation patterns are 
instigated through each of these mechanisms working in concert. 
 
 Histone Modifications 
Post-translational modifications (PTMs) of the N-terminal tails of histone proteins 
change the chromatin structurally and functionally, thereby altering gene expression. 
Histone PTMs include methylation, acetylation, phosphorylation, glycosylation, 
carbonylation, ubiquitylation, biotinylation, sumoylation, citrullination, ADP-
ribosylation, N-formylation, crotonylation, propionylation, and butyrylation, as well as 
proline and aspartic acid isomerization. The sum of all of these histone PTMs is known as 
the histone code 35. Histone PTMs permit, increase or restrict access to chromatin by gene 
regulatory factors. Among the many that have been identified, the most extensively studied 
and best understood histone PTMs in the context of transcriptional competency are 
phosphorylation, methylation, acetylation, and ubiquitination 36.  
Several in vitro studies have demonstrated that iAs exposure can result in global 
changes in histone PTMs. These changes include increases in H3K9me2, H3K4me3, and 
H3S10, decreases in H2B ubiquitination, and either increases or decreases in H3K27me3 
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37-42. In addition, following iAs exposure in humans, blood cells exhibited an overall 
decrease in H3K9me3, and H3K9ac, with an increase in H3K9me2 37,38. Interestingly, 
these studies also showed that the iAs-induced changes in histone PTMs can be gender-
specific. For instance, a decrease in H3K27ac and H3K18ac and increase in H3K4me3 and 
H3K27me3 was observed in iAs-exposed females, while the inverse trend was observed 
in iAs-exposed males 37.  
The majority of PTMs that affect chromatin accessibility are modifications to histone 
H3 (e.g. H3K4, H3K9, H3K27, and H3K36). Methylation of H3K4 is performed by a 
series of type 2 lysine methyltransferases (KMT2) 43 and occurs in a stepwise manner; 
methylation proceeds from the mono- to the di- and, finally, to the trimethylation state. 
While these different H3K4me states can occur throughout a gene, they each exhibit a 
higher presence in specific locations. H3K4me1 most often occurs at the 3’ end of genes, 
H3K4me2 occurs within the gene body, and H3K4me3 often occurs at gene promoters 43. 
Deposition of H3K4me3 at gene promoters and coding regions correlates with 
transcriptional activation 40,44,45. Exposure of cells to iAs results in a global decrease in 
monomethylated H3K4, with a corresponding increase in H3K4’s di- and trimethylated 
states 40. This shift in the global H3K4 methylation status occurs quickly; exposing cells 
to 1 μM sodium arsenite led to changes in H3K4 methylation states in as little as 24 hours 
40. Furthermore, Tyler et al found perinatal arsenic exposure resulted in changes to 
H3K9Ac and H3K4me3 levels in the brains of adult mice 46,47. 
Analogous to H3K4 methylation, H3K9 is first monomethylated and then 
dimethylated by KMT1C (also known as G9a) euchromatic histone methyltransferase. The 
dimethylated state is further converted to the tri-methylated state by KMT1A (also known 
18 
 
as SUV39h1) 39,48. These methylation events are offset by KDM3A, a histone demethylase 
that reverses the mono- or di-methylation of H3K9 39. Like methylated H3K4, the di- and 
trimethylated states of H3K9 are typically found in different chromatin locations; 
H3K9me2 tends to localize at the edges of the nucleus, where heterochromatin is more 
common, while H3K9me3 is found in the center of the nucleus, where euchromatin 
predominates 39,40. Exposure of A549 lung carcinoma cells to iAs increased expression of 
KMT1C, leading to an increase in H3K9me2 and H3K9me3 levels 39. Furthermore, 
Chervona et al. observed a variety of correlations between iAs exposure and this type of 
modification in peripheral blood mononuclear cells using a population-based study in 
Bangladesh. This study further revealed a positive correlation between urinary iAs and 
H3K9me2 37,49.  
H3K27 methylation is another important PTM for histone H3. This repressive PTM 
is mediated by the Polycomb Repressive Complex 2 (PRC2); PRC2 is composed of three 
core components: Enhancer of Zeste 1 or 2 (EZH1/2), Suppressor of Zeste 12, (SUZ12), 
and Embryonic Ectodermal Development (EED). The methylation state conferred by 
PRC2 is determined by the homologue of EZH present in the complex—EZH1 mediates 
the monomethylation of H3K27, while EZH2 mediates its di- and trimethylation. 
H3K27me3 is associated with inactive promoters and gene silencing and, importantly, it 
marks chromatin for further compaction by protein regulator of cytokinesis (PRC1) via 
ubiquitylation of H2AK119 50. iAs exposure greatly increases the expression of the EZH2 
homolog and of other PRC2 core components, resulting in a global increase in H3K27me3 
levels 41. A persistent increase in EZH2 and the subsequent incorporation of H3K27me3 
into chromatin silences the promoters of target genes, which is enhanced by the crosstalk 
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that occurs between epigenetic marks. A clear example of this cross-talk is seen by the 
reduced expressions of p19ARF and p16INK4a due to the incorporation of H3K27me3 
and H3K9me2, and to the methylation of DNA at the INK4/ARF regulatory locus in iAs-
exposed cells 27,51,52.  
It is well known that many changes in histone marks are mediated by histone kinases. 
The kinase-mediated phosphorylation of histone H3 is one example that is associated with 
cell proliferation and transformation 53,54. With regard to arsenic exposure, it is likely that 
iAs activates a cell signaling pathway that modifies histones. For example, iAs induces the 
activation of the nuclear mitogen and stress-activated protein kinase 1 (MSK1) via the p38 
MAPK pathway 19,55, and this process was necessary for iAs-induced transformation 56. 
Interestingly, in response to stress, MSK1 phosphorylates KDM3A (p-KDM3A) at 
Ser264, resulting in the enrichment and recruitment of STAT-1 and p-KDM3A to target 
gene promoters. These events promote the localized demethylation of H3K9 with 
consequential increased transcriptional activity 57. Additionally, MSK1 can directly 
phosphorylate H3S10 58,59, which recruits scaffolding proteins to the promoters of 
immediate early genes, including those of proto-oncogenes FOS and JUN, to induce their 
activation 60.  
Only a few studies have demonstrated a connection between histone phosphorylation 
and arsenic-induced carcinogenicity. Studies have suggested that arsenic-induced H3 
phosphorylation might be responsible for the up-regulation of the oncogenes c-fos and c-
jun 55. Most recently, Ray et al reported that iAs induces a coordinated regulation of Nrf2 
and histone H3S10 phosphorylation, which activates the human heme oxygenase-1 gene 
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42. These results reinforce the notion that iAs modulates gene expression by operating 
through the JNK and p38/Mpk2 kinase pathway to promote cancer.   
iAs may also modulate histone PTMs by activating the epidermal growth factor 
(EGF) pathway 61. Upon activation of this pathway, PKM2—a histone kinase—
translocates to the nucleus, where it binds and phosphorylates Thr11 on histone H3 
(H3T11). This phosphorylation not only accelerates the demethylation of H3K9me3 by 
the trimethylation-specific H3 methylase KDM4C, but also leads to the dissociation of 
HDAC3, allowing the acetylation of H3 with subsequent transcription of oncogenes MYC 
and CCND1 62. By influencing this pathway, iAs may indirectly control the 
phosphorylation and acetylation state of histones and therefore the expression patterns of 
target genes. 
 
 Histone Variants 
In addition to the four canonical histones, there are also highly conserved amino acid 
sequence variants of these histones. The variants differ by only a few amino acids, and 
their expression is generally lower than that of the canonical histones. Each histone variant 
has a specific gene expression, and a distinct chromatin localization/incorporation that 
confers, within the chromatin structure, information contributing to the cell-type, the stage 
of differentiation and tissue. However, compared to the canonical histones, studies on 
histone variants are limited, and so the role these chromatin-incorporated histone variants 
play in normal cells and even in diseased states is only beginning to emerge. Our 
understanding of the impact these histone variants have on chromatin biology is hindered 
by a lack of high-resolution and sensitive assays to differentiate these proteins, as they 
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have very similar amino acid compositions to canonical histones. However, using high-
resolution Top-down mass spectrometry, recent studies from our laboratory showed that 
some histone variants were dynamically altered during iAs-mediated malignant 
transformation. Specifically, we showed that histone H2B variants were abnormally 
expressed following iAs exposure, and during subsequent iAs-mediated epithelial-
mesenchymal transition (EMT) 63.We identified a total of 16 H2B variants, 13 somatic and 
3 testis-specific; of the somatic variants, seven were upregulated while three were 
downregulated 63-67. The most significant changes observed in our study were the 
upregulation of histones H2B1K and H2B1C, and downregulation of histones H2B1D and 
H2B1B. The results demonstrated that although histones are highly conserved, changes in 
single amino acids may influence chromatin dynamics that lead to transcriptional re-
programming critical for cell-type specificity and differentiation 67. Interestingly, removal 
of iAs returned expression levels for some variants to normal levels while others remained 
abnormal, suggesting that some epigenetic changes are transient 63. This iAs removal, and 
its associated reversed gene expression, correlated with a reversal in the variant histones 
expressed during EMT. Therefore, it is possible that the carcinogenic potential seen in 
these cells is driven by expression patterns of histone variants that did not revert following 
iAs removal.  
iAs is known to disrupt the balance between canonical histone H3.1 and variant 
histone H3.3. Histone H3.1 transcription levels are highest during S phase while H3.3 
expression levels are consistently low throughout the cell cycle 68-73. Functionally, histone 
H3.1 is ubiquitously present in genomic chromatin while histone H3.3 is incorporated into 
DNA promoter regions to specifically facilitate transcriptional activation 74,75. iAs 
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treatment increases histone H3.1 stability and genomic incorporation, hindering the 
interaction of histone H3.3 with chromatin and changed nucleosome composition; these 
effects likely change the gene expression patterns 76. Specifically, the irregular 
incorporation of H3.1 could silence tumor suppressor genes and abnormally activate cell 
cycle genes. The proposed mechanism for this iAs-mediated increased influence by H3.1 
involves an associated inhibition of stem-loop binding protein (SLBP) expression 77,78. 
Under normal conditions, SLBP binds to the stem loop on histone transcripts and increases 
their lifetime within the cell. With iAs exposure, SLBP levels are reduced due to reduced 
transcription of the gene and more proteasomal degradation of the protein 70,76. With less 
SLBP present, canonical histone transcripts with the stem loop are degraded, leaving those 
with a polyadenylated tail (H3.1) intact. Indeed, addition of a poly(A) tail to histone 
transcripts increases their stability so they may be present in higher levels outside of S 
phase. This processing ultimately increases H3.1 levels, leading to more nucleosomal 
incorporation, and blocks potential histone H3.3 interactions at strategic sites, causing 
aberrant gene expression 76. Knockdown of SLBP caused increased cell growth and 
transformation, indicating that this mechanism may be implicated in arsenic-induced 
carcinogenesis 76. 
Other histone variants are implicated in carcinogenesis. For example, abnormal 
expression of histone H2A.X, a histone variant involved in double stranded break repair, 
genome stability, and tumor suppression 79-83 has been associated with progression of EMT 
in colon and lung cancer 84,85. When histone H2A.X levels are reduced, the variant is 
depleted from the gene loci for Slug and ZEB1 (EMT markers) creating a relaxed 
chromatin structure and increased expression 84. Upregulation of histone H2A.Z, another 
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histone H2A variant, is implicated in colorectal and breast cancer 86-90. Histone H2A.Z 
contributes to the maintenance of the stability and integrity of the genetic material within 
the cell 91,92. When this variant is upregulated, cell growth and proliferation increase by an 
activation of cell cycle regulators and EMT markers such as E-cadherin and fibronectin 
84,86,93. Yet another set of histone H2A isoforms, H2A.1 and H2A.2, are repressive and 
reduce tumorigenesis 94. These histone variants typically act as tumor suppressors by 
hindering the efficiency of transcription factor binding and chromatin remodeling at 
strategic sites 95-98. Finally, upregulation of CENP-A, a centromere-specific H3-like 
histone, is thought to increase the incidence of aneuploidy and dysregulation of cell cycle-
associated genes, and also is implicated in cancer 99. Further research is needed to 
determine if iAs-induced carcinogenesis and toxicity employ any of these cancer-related 
histone variants.  
 
 MicroRNAs 
MicroRNAs (miRNAs) contribute to another epigenetic mechanism of gene 
regulation affecting development, growth, and the response to stress. Several in vitro and 
human studies demonstrated arsenic-induced alterations in miRNA gene expression. For 
instance, Marsit et al, showed global increases in miRNA expression in response to iAs 
exposure 100. In addition, miR-222 and miR-21 expressions were increased in the 
peripheral blood of steel factory workers exposed to heavy metal particulate 101. In 
contrast, a study of Hong Kong children aged 12–19 years, found decreased expression of 
both miR-21 and miR-221 associated with increased urinary arsenic and lead levels 102. 
Furthermore, in a pregnancy cohort from Mexico, maternal total urinary iAs was 
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associated with the increased expression of 12 miRNAs in infant cord blood. This study 
utilized genome-wide miRNA analysis, and suggests that miRNA alterations can lead to 
gene expression changes in progeny 103. Using transcriptome-wide next generation 
sequencing, Yu and colleagues, identified expression changes for 36 new miRNAs from 
iAs-tainted rice 104. Another study in plants showed that iAs altered the expression of 
miR167, miR319, and miR854 105. Investigations have pursued the function and potential 
mechanism of these microRNA in iAs toxicity. For example, upregulation of microRNA-
21 can enhance the transformation potential of a cell by targeting PDCD4 106. Another 
functional mechanism identified is the iAs-mediated transformation in p53(low) HBECs, 
which can be reversed by homeobox factor 1 (ZEB1 and ZEB2)-mediated increases in the 
levels microRNA 200b107. Also identified, iAs-mediated autophagy is supported by 
microRNA-21-induced PTEN-ERK signaling, and iAs-induced angiogenesis occurs 
through a microRNA425-5p-regulated CCM3 108. With the help of new technology, 
additional iAs-associated miRNAs functions and processes will be discovered, revealing 
the regulatory network that mediates iAs toxicity and carcinogenesis. 
 
 Alternative Splicing 
Epigenetic regulation of gene expression occurs at the level of transcriptional 
activation, as discussed above, but also through the less investigated process of splicing. 
Alternative splicing (AS) of pre-mRNA occurs in many multi-exon genes and greatly 
increases the diversity of the proteome. Aberrant splicing is known to occur in human 
cancers 109-111, and a proposed mechanism is the substitutions of isoforms associated with 
carcinogenesis 112, angiogenesis 113 and EMT 114,115. Epigenetic modifications are thought 
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to regulate AS by two non-mutually exclusive means: 1) by affecting the kinetics of 
polymerase elongation and 2) through recruitment of splicing regulatory factors. Two 
types of epigenetic marks, DNA methylation 116-119 and histone PTMs 111,120-123, have been 
implicated in the selection of exon-candidates. Exposure to iAs significantly alters DNA 
methylation 124 and histone PTMs 38-40,52,125-127, and so it is reasonable to expect that this 
exposure can induce changes in alternative splicing. Indeed, we recently showed that low-
dose iAs exposure results in changes in AS 124, though the mechanism remains unknown.  
One possible mechanism by which iAs influences AS may be through an inhibition 
of DNA binding by alternative splicing regulators such as CCCTC-binding factor (CTCF) 
and poly (ADP) ribose polymerase (PARP1) 123,128,129,. Interestingly, PARP1 co-localizes 
with CTCF on chromatin; this complex, with CTCF-dependent automodification of 
PARP1, permits PARylation activity in the absence of DNA damage 128,130. Importantly, 
many splicing factors are regulated by PARylation 131-135 and any iAs-mediated inhibition 
of PARP1 binding to DNA not only affects the structural properties of chromatin but also 
the PARylation activities, which indirectly affect splicing decisions. In addition, the 
binding of proteins to DNA can be altered by the presence of iAs due to the high binding 
affinity of this metalloid for cysteine residues that are found in C4 and C3H1 zinc finger 
motif-containing proteins such as PARP1 136-138. Other DNA-binding proteins with zinc 
finger motifs inhibited by iAs are the methylcytosine dioxygenases (TET1/2), needed to 
oxidize 5-methylcytosine to 5-hydroxymethylcytosine and 5-carboxylcytosine 139. 
Inactivation of TET1/2 by iAs allows 5-methylcytosine to accumulate at CTCF target sites 
and prevents CTCF from binding to its target sites, resulting in exon exclusion 117. In 
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summary, if iAs blocks the binding of PARP1 or CTCF to DNA, the chromatin-associated 
functioning of these proteins is altered, which includes splicing decisions. 
A second possible mechanism by which iAs may alter AS is by increasing the 
presence of p52 through activation of the non-canonical NF-κB pathway 140. P52 co-
localizes and interacts with the splicing factor SRSF1 to modulate splicing 120. The role of 
SRSF1 in carcinogenesis is well studied 141, and its expression is upregulated by MYC 142, 
which in itself is deregulated in iAs exposure 24,143. MYC also directly upregulates core 
pre-mRNA machinery during carcinogenesis and maintains appropriate splicing of 
alternative exons 144. 
The dominant isoform expressed for any given gene is tissue specific and may result 
from differentially expressed splicing regulatory factors among tissue types 145-147. Since 
changes in AS are likely to vary from tissue to tissue, dissecting and understanding the 
complicated issue of what drives iAs-mediated carcinogenesis is complex task. 
 
 Conclusion 
 A large body of research has implicated low dose arsenic exposure in 
carcinogenesis and EMT. This review examines the impact of epigenetic processes, 
including DNA methylation, histone PTMs, histone variants, and alternative splicing, on 
carcinogenesis mediated through iAs exposure. While all of these epigenetic marks are 
associated with iAs-induced carcinogenesis, additional research is required to clarify the 
mechanism(s) driving each system. Expanded research in this area will delineate the role 
of iAs exposure in the initiation and development of cancer. 
  
27 
 
Figure 1.1 Estimated population with arsenic greater than 10 micrograms per liter. 
 
 
Map showing estimated population in each county in the United States that is exposed to 
arsenic via groundwater above 10 µg/L. (Figure from United States Geological Survey) 
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CHAPTER 2. MATERIALS AND METHODS 
 HeLa Cell Growth and Arsenic Treatment 
HeLa cells were grown using Dulbecco’s modified Eagle medium (DMEM; Sigma-
Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 1% MEM 
nonessential amino acids (Sigma-Aldrich), and 1% penicillin-streptomycin (Sigma-
Aldrich). Cells were grown in a humidified chamber at 37°C and 5% CO2 until they 
reached 80% confluency. For iAs exposure (iAsT cells), cells were treated with 0.5 µM 
sodium arsenite (Sigma-Aldrich) for approximately 45 days. Time matched controls were 
treated with water (nontreated or NT cells). Reverse-treated cells (RT cells) were treated 
with 0.5 µM sodium arsenite until day 36, at which point they were treated with water 
instead of sodium arsenite. Reverse-treated cells were harvested 10 days after treatment 
reversal (day 46). 
 
 BEAS-2B Cell Growth and Arsenic Treatment 
BEAS-2B cells were grown using DMEM (Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (Sigma-Aldrich), 1% MEM nonessential amino acids (Sigma-Aldrich), 
and 1% penicillin-streptomycin (Sigma-Aldrich). Cells were grown in a humidified 
chamber at 37°C and 5% CO2 until they reached 80% confluency. For W3, W8, and W17 
treatment groups, cells were treated with 0.5 µM sodium arsenite (Sigma-Aldrich) for 
three, eight, and seventeen weeks, respectively. Cells in the 2.0T treatment group were 
grown with 0.5 µM sodium arsenite for 20 weeks, and then grown in 2 µM sodium arsenite 
for six weeks. Time matched controls were treated with water (nontreated or NT cells). 
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Reverse-treated cells (RT) were treated with 0.5 µM sodium arsenite for 20 weeks, then 
treated with 2 µM sodium arsenite for six weeks. This was followed by three weeks of 
growth without sodium arsenite treatment. Reverse-treated cells were harvested 3 weeks 
after treatment reversal. 
 
 Quantification of the 5-Methylcytosine Level in DNA 
Genomic DNA was isolated from the cells and total 5-methylcytosine (5-mC) was 
determined using the 5-mC DNA ELISA kit (Zymo Research Corp.) according to the 
manufacturer’s instruction. Briefly, DNA is denatured and then treated with an anti-5-
methylcytosine monoclonal antibody that is both sensitive and specific for 5-mC. A 
secondary antibody containing horseradish peroxidase is then used to detect 5mC. Values 
are expressed as a percent 5-mC in a DNA sample calculated through a standard curve 
generated with specially designed controls that are included in the kit. Each ELISA was 
performed in triplicate and students t-test performed to determine statistical significance. 
 
 Infinium MethylationEPIC Bead Chip – Methylation array analysis 
Sample preparation for the Chip. Genomic DNA from nontreated, treated, and 
reverse treated cells was extracted using the Qiagen DNeasy Blood and Tissue kit; samples 
were initially bisulfite converted using the Zymo EZ-96DNA Methylation Kit (Catalog 
#D5004) Deep-Well Format. DNA was treated with sodium bisulfite causing 
unmethylated cytosines to convert to uracil while keeping methylated cytosines 
unchanged. Then, 4µl (equivalent to 750ng DNA) of the bisulfite-converted DNA was 
used as input for the Illumina Infinium HD Methylation Array. During this process, the 
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bisulfite converted DNA samples were denatured, neutralized, and prepared for 
amplification. The amplified DNA was enzymatically fragmented and precipitated. The 
resuspended DNA samples were then dispensed onto Illumina's Infinium 
MethylationEPIC BeadChip148, where they underwent a series of washing, extension, and 
staining procedures. The BeadChips are then coated for protection and scanned on the 
Illumina HiScanHQ. Once scanning was completed, the data were uploaded into 
GenomeStudio for preliminary and quality control analysis. 
Data analyses. Target success rates were determined and the detection p-value was 
calculated as 1-p from the background model characterizing the chance that the target 
sequence was distinguishable from the negative control148. Poor performing targets were 
defined as having p>0.05 and were discarded. Sample replicates were checked for an r2 
value greater than 0.99. For statistical analysis, beta values were calculated. The 
methylation levels of CpGs were described as beta values (0 to 1) representing the 
calculated level of methylation (0% to 100%). We had two technical and two biological 
replicates processed by chip technique. The Pearson correlation coefficients (PCCs) were 
>0.99 for all the replicates, confirming a good level of reproducibility for the chip process 
and indicating that the observed differential methylation between the cells (treatments) 
represented true biological differences. Functional normalization was performed using 
home scripts ‘Minfi preprocessFunNorm’ which does the background normalization. 
Additionally, the dye correction was performed using noob149. All CpG sites with a 
detection value > 0.05, CpG sites with SNPs, as well as probes predicted to hybridize to 
more than one genomic location (identified by McCartney et al. in Genomics Data, 2016) 
were removed. 
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 Isolation of Total RNA and Production of cDNA 
RNA was isolated from 1x107 cells using the RNeasy Plus Mini Kit (Qiagen). RNA 
was eluted in 0.5X TE. One microgram of RNA was used in a reverse transcriptase reaction 
with iScript Reverse Transcriptase (Bio-Rad) to prepare cDNA and cDNA was diluted 
1:10 in water.  
Recipes 
0.5X TE: 5 mM Tris, 0.5 mM EDTA pH 8.0 
 
 Isolation of PolyA RNA and Production of cDNA 
For extraction of polyadenylated RNA, total RNA was extracted from approximately 
ten 1x107 cell pellets and combined to collect 10 µg of total RNA for each BEAS-2B 
treatment group. Polyadenylated mRNA was isolated from approximately 10 µg of total 
RNA using the PolyATtract mRNA Isolation System (Promega). One microgram of polyA 
mRNA was used in a reverse transcriptase reaction with poly(dT) primers with the 
Superscript IV First-Strand Synthesis System (Thermo Fisher Scientific) to prepare cDNA 
and cDNA was diluted 1:20 in water. 
 
 Quantitative Real Time PCR 
Each quantitative real-time PCR (qRT-PCR) reaction contained 25 ng of cDNA and 
followed a variation of the following reaction protocol: 1) 94°C for 5 min; 2) 94°C for 30 
sec; 3) 50-65°C for 30 sec; 4) 72°C for 45 sec; 5) repeat 2-4 for 40 cycles; 6) 72°C for 10 
min. Reactions were run and data was collected on Bio-Rad CFX96 Real Time System. 
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Primers are listed in supplementary table. qRT-PCR data was analyzed by the 2-ddCt method 
and student t-tests were performed to determine statistical significance. 
 
 Histone Extraction 
1x107 BEAS-2B cells were resuspended in 1 ml of TEB and incubated with shaking 
at 4°C for 10 minutes, then centrifuged at 3000 RPM for 10 minutes at 4°C. The pellet was 
then washed again in TEB and centrifuged. The remaining pellet was incubated in 0.2N 
HCl and incubated with shaking overnight at 4°C. The lysate was then centrifuged for 10 
minutes at 4°C and the supernatant was dialyzed against two changes of 0.1N acetic acid 
for 2 hours each. This was followed by dialysis against three changes of water, with the 
last dialysis going overnight. Histones were removed from the dialysis tubing and 
concentrated using Amicon Millipore Ultra-10 centrifugal filter units. Histone extract 
purity was determined using Western Blot analysis. 
Recipes 
TEB: 2 mM PMSF, 0.01% NaN3, 0.005% TritonX100, in Dulbecco’s phosphate buffered 
saline 
 
 Western Blot 
For whole cell protein extraction, 5x106 HeLa or BEAS-2B cells were homogenized 
in 1X RIPA buffer and then intermittently sonicated with 12 cycles of 30s bursts/30s rest 
(Diagenode Biodisruptor 300). Cell lysate was then centrifuged at 13000 rpm at 4°C for 
15 minutes to pellet cell debris. For nuclear protein extraction, 1x107 HeLa or BEAS-2B 
cells were resuspended in a hypotonic solution and kept on ice for 15 minutes. Then, NP-
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40 was added to the cellular lysates to a final concentration of 0.5% and the lysates were 
centrifuged at 3000 RPM for 10 minutes 4°C to remove cellular debris, leaving only the 
nuclei. The nuclei were then resuspended in 1X RIPA and kept on ice for 30 minutes. This 
was followed by centrifugation at 13,000 RPM for 30 minutes at 4°C to remove nuclear 
debris. Whole cell and nuclear protein concentration was measured using a BCA kit 
(Thermo Fischer Scientific) and 50-100 µg of total protein were run on a 15% SDS-PAGE 
gel at 120 V until loading dye (GoldBio) reached the bottom of the gel. Proteins were 
electrotransferred to polyvinylidene fluoride membranes (PVDF) at 65 V for 90 min on 
ice. 5% milk + phosphate buffered saline with Tween (PBST) was used to block non-
specific binding to the membranes. Membranes were incubated with primary antibodies 
(in 0.5% nonfat powdered dry milk + PBST) overnight at 4°C and then with secondary 
antibody (α-Rabbit or α-Mouse) the next day. Proteins were visualized with ECF (GE-
Typhoon FLA9500) as outlined by the manufacturer. 
Recipes 
1X RIPA: 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM 
Tris-HCl pH 7.4 
Hypotonic Solution: 20 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2 
15% SDS-PAGE Separating Gel: 15% Acryl/Bis 29:1, 0.375 M Tris pH 8.8, 0.1% SDS, 
0.1% APS, 1X TEMED 
4% SDS-PAGE Stacking Gel: 4% Acryl/Bis 29:1, 0.125 M Tris pH 6.8, 0.1% SDS, 0.1% 
APS, 1X TEMED 
1X PBST: 0.0002% Tween in phosphate buffered saline 
Blocking Buffer: 5% dry milk powder, 1X PBST 
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 Actinomycin Treatment 
To analyze decay rate of histone H2B transcripts, 1x106 BEAS-2B cells for each 
treatment group were plated in each well of a 6-well plate with 2 ml of liquid media. 
Actinomycin D (Sigma) was added to each well to a final concentration of 5 ug/ml. 
Treatment was stopped at 0 hours, 30 min, 60 min, and 4 hours by adding trypsin and 
pelleting cells by centrifugation at 3000 RPM for 3 minutes. qRT-PCR was performed for 
several histone H2B variant transcripts to detect mRNA levels. Decay was determined 
using 0 time point as control.150 
 
 Salt Fractionation of Chromatin 
Salt fractionation begins with chromatin extraction and digestion. For chromatin 
extraction, 5x106 BEAS-2B cells from each treatment group were lysed in TM2 buffer 
containing a final concentration of 0.5% NP40 for 5 minutes on ice with gentle vortexing. 
Cellular debris was removed by centrifugation at 2000 RPM for 5 minutes at 4°C. This 
was followed by a 10 minute wash in TM2 buffer and another centrifugation. For 
chromatin digestion, the appropriate concentration of micrococcal nuclease (MNase, 
Thermo Fisher Scientific) and length of digestion must be experimentally determined. In 
my experiments, chromatin was MNase digested at an MNase concentration of 5 U/ml for 
15 minutes at 37°C. Digestion was stopped with the addition of EGTA to a final 
concentration of 8 mM. A portion of the sample was removed and saved as the “Nuc” 
fraction. Then, the remaining sample was centrifuged at 2000 RPM for 10 minutes at 4°C 
to remove cellular debris and a portion of the supernatant was removed and saved as the 
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“Sup” fraction. The remaining pellet was incubated in a Triton buffer containing 80 mM 
salt for 2 hours at 4°C with rotation. After this incubation, chromatin was pelleted by 
centrifugation at 2000 RPM for 10 minutes at 4°C and the supernatant was collected as the 
“80 mM” fraction. This incubation with Triton buffer containing salt was repeated with 
increasing concentrations of NaCl (150 mM, and 600 mM NaCl) for 2 hours. After each 
incubation, the sample was centrifuged and supernatant was taken. After all three 
incubations with Triton buffer, the final pellet was resuspended in TNE buffer. To detect 
DNA content, 50 µl of each fraction was incubated with 2 mg/ml Proteinase K for 1 hour 
at 37°C and then purified with PCR Cleanup (Qiagen). DNA was eluted in 0.5X TE and 
run on an agarose gel. To detect protein content, 15 µl of each fraction was loaded onto an 
SDS-PAGE gel. For both DNA and protein gels, band size and density were measured and 
compared. 
Recipes 
TM2 Buffer: 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 0.5 mM PMSF 
TNE Buffer: 10 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA 
80 mM Triton Buffer: 70 mM NaCl, 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 2 mM EGTA, 
0.1% Triton X-100, 0.5 mM PMSF 
150 mM Triton Buffer: 140 mM NaCl, 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 2 mM EGTA, 
0.1% Triton X-100, 0.5 mM PMSF 
600 mM Triton Buffer: 585 mM NaCl, 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 2 mM EGTA, 
0.1% Triton X-100, 0.5 mM PMSF 
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 Nucleosome Reconstitution 
Mononucleosomes were reconstituted using double dialysis of free 147 bp 601 
DNA151 and histone octamer, with DNA present in molar excess (1:25 to histone octamer). 
Dialysis occurred with two changes against “no salt” reconstitution buffer, one for six 
hours and one overnight. After dialysis, the contents of the dialysis button were extracted 
and nucleosomes were separated from free DNA using a sucrose gradient. The sucrose 
gradient was made (as described below) and the contents of the dialysis button were gently 
loaded on top. The sucrose gradient was centrifuged for 22 hours at 41,000K at 4°C using 
a Ti-41 rotor. After centrifugation, the sucrose gradient was fractionated by hand into 400 
µl fractions. The fractions were kept on ice and fractions 8-27 were run on a 5% TBE 
native gel for 1.5 hr at 300 V. Native gels were stained in 1X GelStar™ Nucleic Acid Gel 
Stain (Lonza) in 1X TBE for 30 minutes and imaged on a Typhoon FLA 9500 (GE 
Healthcare) using the ECF filter. Fractions containing nucleosome and no contaminating 
DNA were combined, concentrated, and buffer exchanged into 0.5X TE using Millipore 
Amicon Ultra-15 centrifugal filter units. 
Recipes 
Reconstitution Buffer with 2M NaCl: 0.5X TE, 1 mM benzamidine hydrochloride, 2M NaCl 
Reconstitution Buffer without NaCl: 0.5X TE, 1 mM benzamidine hydrochloride 
 
 Sucrose Gradient 
Sucrose gradients were made using the BioComp model 108 gradient master™ 
according to manufacturer protocol. An SW-41Ti tube containing 30% sucrose in the 
bottom portion and 5% sucrose in the top portion was rotated on the Gradient Master 
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Platform for 1 minute and 36 seconds at an 81.5° angle at speed 19. Sucrose gradients must 
be made fresh using chilled sucrose solutions and used immediately to prevent diffusion 
and loss of gradient. The sucrose solutions were stored at 4°C. 
Recipes 
5% Sucrose: 5% sucrose in 0.5X TE (W;V) 
30% Sucrose: 30% sucrose in 0.5X TE (W:V) 
 
 Thermal Stability Assay 
 For each reaction, a master mix of reagents and either octamers or nucleosomes 
was created and pipetted into individual wells of a 96 well plate. Then, SYPRO Orange 
(Thermo Fisher Scientific) was added to a final concentration of 5X. Each reaction was 
run on the Bio-Rad CFX Real-Time Detection System with a protocol that increased the 
temperature by one degree each minute from 20-90°C. For each run, replicates were 
averaged and normalized and the melting temperature, at which point the slope was the 
steepest on the melting curve, was determined. 
Recipes 
Reaction Mixture with Octamer: 2.25 µM histone octamer, 5X SYPRO Orange, 20 mM 
 Tris-HCl pH 7.5, 1 mM DTT, 2M NaCl 
Reaction Mixture with Nucleosome: 0.5 µM histone octamer, 5X SYPRO Orange, 20 mM 
Tris-HCl pH 7.5, 1 mM DTT, 2M NaCl 
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 MNase Digestion 
601 DNA containing 50 bp linker DNA on either end was created containing P32 α-
ATP. DNA was run on 14% TBE native gel and band containing DNA was cut out. DNA 
was incubated in Crush-N-Soak Buffer overnight and ethanol precipitated. Radiolabeled 
DNA was then concentrated and buffer exchanged into 0.5X TE 20 mM NaCl. 
Nucleosomes were reconstituted according to protocol above. 50 ng of nucleosomes were 
incubated with 10 U/µl MNase for increasing amounts of time and stopped using stop 
solutions. Then, digested DNA was purified from reaction mixtures using Qiagen PCR 
Cleanup Kit. DNA was eluted in 30 µl 0.5X TE, mixed with Orange G (Sigma Aldrich), 
and run on 5% TBE gel for 1.5 hours. Gels were placed on screen overnight and imaged 
using Typhoon. 
Recipes 
Crush-N-Soak Buffer: 0.75 M ammonium acetate, 0.3 M sodium acetate, 1 mM EDTA pH 
8.0, 0.1% SDS 
Reaction Mixture: 50 ng nucleosome, 1.5 mM CaCl2 100 ug/ml BSA, 5% glycerol, 25 mM 
NaCl, 1 mM DTT, 10 mM Tris pH 7.4, 10 U/ml MNase 
Stop Solution 1: 0.25 M EDTA, 0.1 M EDTA 
Stop Solution 2: 10 mg/ml, 0.1% SDS, 0.02 M EDTA 
5% TBE Gel: 5% Acryl/Bis 29:1, 10% ethylene glycol, 1X TBE, 0.1% SDS, 1X TEMED 
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CHAPTER 3. TRANSIENT AND PERMANENT CHANGES IN DNA 
METHYLATION PATTERNS IN INORGANIC ARSENIC-MEDIATED 
EPITHELIAL-TO-MESENCHYMAL TRANSITION 
 Introduction 
Environmental inorganic arsenic (iAs) exposure through contaminated water 
consumption represents a major public health concern 1,152-155 and has been linked to 
cardiovascular diseases 6,152, diabetes 156, and a variety of cancers including lung 157, 
colorectal 158, kidney 157, liver 22,157 and skin cancers 159,160. Inorganic arsenic is not a direct 
mutagen, rather it acts through other mechanisms to induce cellular transformation and 
epithelial-to-mesenchymal transition (EMT) 13,161. Several mechanisms have been 
proposed to describe how iAs-induced toxicity promotes carcinogenesis; these include the 
induction of oxidative stress 162-164, inhibition of DNA repair, and chromosomal 
aberrations 13,165. In addition to these mechanisms, recent findings indicate that epigenetic 
factors, such as DNA methylation, play a central role in aberrant gene expression resulting 
from iAs exposure 39,136,166,167.  
DNA methylation, the most stable epigenetic mark, is a key factor in regulating gene 
expression 168,169. This mark is added to DNA by DNA methyltransferases (DNMTs); 
DNMT1 is responsible for the maintenance methylation while DNMT3a and DNMT3b 
perform de novo methylation 170,171. DNA methyltransferases facilitate this modification 
by the transfer of a methyl group from S-adenosyl methionine (SAM) to the 5’ carbon of 
cytosine residues 170. This modification normally occurs in regions/contexts of high CpG 
density, known as CpG islands (CGIs). However, DNA methylation can also occur in non-
CGI contexts. CGIs are typically concentrated at promoter regions but can be found in 
other regions 172 and methylation controls gene expression differently depending on its 
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location. The presence of 5-methylcytosine at promoters is usually associated with 
transcriptional repression 172. Conversely, absence of this mark, along with the presence 
of the appropriate transcription factors, promotes gene expression. However, within gene 
bodies and at intergenic regions, the effects of methylation are less definitive; therefore, 
studies are in process to elucidate the dynamic effects of DNA methylation in those 
contexts. Since methylation can affect transcription factor binding ability 173, it is possible 
that DNA methylation functions prominently in cell and tissue identity and functionality.  
Several mechanisms have been proposed to describe how iAs affects the DNA 
methylation profile in cells. The first involves the metabolism of inorganic arsenic. During 
iAs metabolism, arsenic methyltransferase (AS3MT) transfers a methyl group to arsenite, 
using SAM as a donor 24; this process could lead to a depletion of SAM, which is needed 
for a variety of other cellular processes and the sole donor for DNA methylation. A second 
mechanism involves changes in the expression of DNMTs in response to chronic exposure 
to iAs. In trying to understand why DNMTs would be targeted, we found that the 
transcriptional repressor CTCF is targeted by iAs treatment, causing changes in CTCF 
occupancy at DNMT promoters 174-176. Such disruption in the DNMT expression would 
effect changes in DNA methylation patterns.  
Several studies that focus on profiling of the global changes in DNA methylation 
levels have been carried out in cells exposed to iAs; however, these studies have used low-
resolution genome profiling techniques to investigate methylation patterns 177. Clearly 
missing is an analysis of DNA methylation patterns at gene regulatory regions such as 
CpG islands, promoters, and enhancers. Recently, we carried out the first comprehensive 
study of DNA methylation changes with single-nucleotide resolution for cells chronically 
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exposed to low doses of arsenic 174. In the present study, we extend our findings to 
determine changes in iAs-induced DNA methylation patterns in cells with chronic low-
dose iAs exposure, as well as in cells that undergo a reversal of this treatment. Our studies 
include the analysis of DNA methylation profiles and correlations of gene expression 
changes in the cells, combining unbiased whole-genome and candidate gene approaches.  
In this study, we aim to determine the effect of iAs on both permanent and reversible 
changes in DNA methylation and gene expression that drive EMT. Our lab previously 
showed that removal of iAs resulted in a reversal of some gene expression patterns 63,124. 
We reasoned that since epigenetic marks are reversible, some methylation patterns would 
revert to the nontreated condition when iAs is removed, thereby reversing some gene 
expression patterns, while others would remain stable. We therefore investigated the 
adaptive changes after reversal of the exposure. 
 
 Results 
3.2.1 Cellular Transformation and EMT 
To determine the effect of iAs on the epithelial-to-mesenchymal transition (EMT), 
we used the common cervical cancer cell line, HeLa, which has been used extensively to 
study cell signaling and EMT 124,178,179. Interestingly, though carcinogenic, HeLa cells can 
still undergo EMT 180, and specifically, iAs-induced EMT 63,124. In our experimental design 
(Figure 3.1A), HeLa media was replenished with 0.5 µM sodium arsenite every three to 
four days for 45 days to allow cells to undergo iAs-mediated EMT (iAsT). This low-dose 
treatment simulates chronically exposed, environmentally relevant iAs levels that many 
people in mining regions experience 1,2,181. We confirm our previous results showing that 
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chronic low-dose treatment of cells with iAs resulted in epithelial-to-mesenchymal 
transition in HeLa cells 63,124,174. In addition, after continuous exposure, iAs was removed 
from some cultures and those cells were grown in media without iAs for 10 more days. 
We called this period of treatment without iAs “inorganic arsenic exposure reversal” (iAs-
rev) and its purpose is to simulate situations where people are removed from chronic iAs 
exposure (Figure 3.1A).  
In previous studies, we observed EMT through cell morphology as well as through 
qRT-PCR and western blot analyses of EMT markers 63,124,174. Morphologically, we 
observed that NT cells maintained an epithelial phenotype in which cells were round and 
small. Upon iAs treatment, cells developed a more mesenchymal phenotype, being 
elongated and spindle-shaped, suggestive of EMT 63,124. Through qRT-PCR and western 
blot analyses, we observed changes to cellular markers characteristic of cells undergoing 
the EMT process. Cell adhesion markers, such as β-catenin, Claudin-1, Claudin-3, and 
ZO-1, are expected to decrease in expression while transcription factors that promote a 
mesenchymal phenotype, such as Snail, Slug, and Vimentin, are expected to increase in 
expression 63,124. Additionally, upon reversal of treatment, we found that some EMT 
markers exhibited a moderate reversal in expression and protein levels (β-catenin, Slug, 
and Snail) while others did not revert (Claudin-3 and Vimentin) 63. To validate that EMT 
is occurring in our current studies, we analyzed protein expression changes for EMT 
markers using western blot analysis and the changes in protein levels indicate that the cells 
indeed had undergone EMT (Figure 3.1B). We found that Claudin-1 decreased in protein 
levels upon treatment and that Slug, N-cadherin, and Snail increased upon treatment. After 
reversal of treatment, some markers exhibited a moderate reversal such as Slug and N-
43 
 
cadherin, indicating that there was some reversal of the EMT conditions albeit not 
completely. Conversely, Claudin-1 and Snail did not revert back toward non-treated levels, 
which we also saw in previous studies (Figure 3.1B). These results corroborate our 
previous data, indicating that cells treated with low doses of inorganic arsenic undergo 
EMT and that this transition is partially reversed when inorganic arsenic is removed.  
 
3.2.2 Global DNA methylation level 
After demonstrating that HeLa cells undergo EMT in response to iAs treatment and 
partial reversal with iAs withdrawal, we next identified the DNA methylation changes 
present in iAsT and iAs-rev cells. We first determined the levels of global DNA 
methylation in these samples using the Zymo 5-mC DNA ELISA assay. We found 
significantly higher DNA methylation levels in iAsT cells compared to NT cells (Figure 
3.2). In line with our reversal of EMT markers, we observed a reduction in global DNA 
methylation levels in iAs-rev cells compared to iAsT cells, and the amount of DNA 
methylation more closely resembled those in NT cells (Figure 3.2). We interpret these data 
as indicating that global DNA methylation is reprogrammed in these cells and may 
correlate with changes in gene expression patterns. 
 
3.2.3 Quantification of DNA methylation at specific sites 
Since the 5mC DNA ELISA assay is a low-resolution technique that measures DNA 
methylation levels, the Infinium MethylationEPIC BeadChip Array was used to further 
interrogate the differential methylation patterns globally, and at specific genes targeted in 
iAs-mediated EMT and reversal. This array has 853,307 CpG (850K) sites, providing the 
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ability to interrogate DNA methylation changes not only at promoters and gene bodies, 
but also at unexplored regions such as enhancers148. Indeed, incorporated into this Chip 
are 333,265 CpG sites, including enhancer regions identified by the ENCODE 182,183 and 
FANTOM5 184 projects. Thus, this is a valuable tool to decipher how DNA methylation 
changes in unexplored territories, such as enhancer sequences, contribute to arsenic-
mediated diseases.  
 
3.2.4 Global Methylation Changes 
To identify possible targets for iAs-mediated DNA methylation reprogramming, we 
conducted methylation profiling of the NT, iAsT, and iAs-rev cells. We filtered DNA 
methylation data according to the following criteria: methylation changes should be more 
than two-fold and should have a p-value < 0.05 (Supplemental Figures 3.1 and 3.2). Of the 
853,307 CpG sites, significant differences in DNA methylation were observed at 30,530 
unique CpG sites in iAsT when compared to NT, of which 67% (20,314 CpG) were 
hypermethylated and 33% (10,216 CpGs) were hypomethylated (Figure 3.3). Upon 
reversal of arsenic treatment, some of the methylated sites did not revert to normal 
methylation in NT conditions. A total of 53% of the DMRs still differed from NT cells; 
77% of these CpGs (10,996 CpGs) were hypermethylated, while 23% (3,3339 CpGs) were 
hypomethylated (Figure 3.3). We then compared the DMRs in iAsT cells and iAs-rev cells. 
We observed that ~40,000 sites had reverted towards the wildtype status - 20,997 
hypomethylated and 20,589 hypermethylated (Figure 3.3). We hypothesize that although 
many DMRs revert to NT conditions, some were not reversed completely and so were still 
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measured as DMRs by our analysis. While these global measurements are useful, they do 
not show differential methylation at specific gene regulatory regions. 
  
3.2.5 iAs-mediated DNA methylation changes in CGIs and non-island regions 
Methylation is often concentrated at CGIs but can also be found in the regions 
surrounding CGIs (Figure 3.4A). According to Illumina, a CGI is defined as a region in 
which there is GC content greater than 50% in at least a 200 base pair region148. 
Comparative analysis of the methylation patterns in CGIs, shores, shelves and open seas 
revealed significant differences in methylation patterns across NT, iAsT, and iAs-rev cells 
in certain CGI-related regions. The shelves (2000-4000 bp from CpG island, in blue), 
across all of the comparisons, only exhibited 2-3% hypo- or hypermethylation changes, 
indicating that DNA methylation of these specific regions may not play a prominent role 
in iAs-mediated EMT (Figure 3.4B-D, all pie charts). For the shores (less than 2000 bp 
from CpG island, in purple), a slight decrease in hypomethylation was observed when 
comparing iAs-rev v. NT and iAsT v. NT (Figure 3.4B and C, top pie charts). The most 
prominent changes in hypomethylation were observed within the CGIs (in orange) and 
open sea regions (over 4000 bp from CpG island, in green). There was an increase in 
hypomethylation (15% to 25%) at CGIs upon reversal (Figure 3.4B and C, top pie charts). 
On the other hand, in the open sea regions, the amount of hypomethylation was reduced 
upon reversal (55% to 49%) (Figure 3.4B and C, top pie charts). This shift in the ratio of 
CGI to open sea hypomethylation could suggest that hypomethylation changes at the CGIs 
are more permanent while hypomethylation changes at the open seas are more transient 
and more prone to reversal when iAs treatment is removed. 
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In the shores (in purple), a slight increase in hypermethylation was observed when 
comparing iAs-rev v. NT and iAsT v. NT, which compensates for the slight decrease in 
hypomethylation, noted above (Figure 3.4B and C, bottom pie charts). This shift in 
differential methylation at the shores was confirmed by the presence of more 
hypermethylation than hypomethylation in the iAs-rev v. iAsT comparison in Figure 3.4D. 
This finding could suggest that the changes in the hypomethylated loci are more transient, 
or that the hypermethylation previously observed in treated cells is more permanent. At 
the CGIs, there is an increase in hypermethylation (11% to 14%) upon arsenic withdrawal, 
similar to the increase in hypomethylation in that region (Figure 3.4B and C, bottom pie 
charts). For iAs-rev v. iAsT, the CpG islands exhibited 12% hypomethylation and 13% 
hypermethylation (Figure 3.4D). In the open sea regions, the amount of hypermethylation 
was reduced from 66% to 61% upon reversal (Figure 3.4B and C, bottom pie charts). Both 
hypo- and hypermethylation were reduced to a similar extent in the open seas after arsenic 
treatment was removed. When comparing iAs-rev to iAsT, the open sea represented 64% 
of the hypomethylated regions and 58% of the hypermethylated regions (Figure 3.4D). 
The decrease in hypermethylation at the open seas and the increase in hypermethylation at 
CGIs after iAs withdrawal (which was also seen with hypomethylation) could indicate that 
differential methylation in the open seas is not as permanent as differential methylation in 
the CGIs.  
 
3.2.6 iAs-mediated DNA methylation changes in Genes and Gene Regulatory Regions 
There are several regulatory regions within a gene that modulate gene expression and 
repression (Figure 3.5A). We asked if there were any transient and/or permanent iAs-
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mediated methylation changes within these regions. We compared the methylation profiles 
across different regions of genes – 5’ and 3’ UTRs (orange and gray respectively), gene 
body (purple), first exon (green), and regions 200 and 1500 base pairs (bp) upstream to the 
transcription start sites (TSS200 blue and TSS1500 red). When compared to NT cells, 
differential hypomethylation in iAsT cells is as follows – 25% at TSS1500, 11% at 
TSS200, 15% at 5’UTR, 6% at first exon, 41% within the gene bodies and 2 % within the 
3’UTR (Figure 3.5B, left bar). In all regions analyzed, there is a similar amount of hypo- 
and hypermethylation changes, except at the gene body and TSS1500, where we observed 
41% hypomethylation to 49% hypermethylation and 25% hypomethylation to 19% 
hypermethylation. (Figure 3.5B). We next asked if these methylation changes can be 
reversed by comparing DNA methylation patterns in NT cells and iAs-rev cells. Focusing 
mainly on the regions that were strongly differentially methylated, we first observed a 30% 
hypomethylation and a 45% hypermethylation change within the gene body (Figure 3.5C). 
This seems to indicate a reversal of methylation patterns when considering the changes 
seen in iAsT cells in the gene body region. Surprisingly, we also observed a dramatic 
change in methylation at the first exon – 22% hypomethylation and 6% hypermethylation 
(Figure 3.5C). However, our understanding of the implication of this shift in 
hypomethylation towards the first exon at the moment is not clear. Furthermore, the 
TSS1500, which exhibited 25% hypomethylation and 19% hypermethylation in iAsT cells 
compared to NT cells (Figure 3.5B), also exhibited differential methylation in the reverse 
treated cells (Figure 3.5C). In reversed conditions, compared to NT cells, the differential 
methylation pattern is 18% hypomethylation and 20% hypermethylation, which is the 
opposite of what was observed in iAsT cells, indicating that reversal of methylation 
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patterns may be occurring upon removal of iAs treatment. In most cases, we observed 
some reversal in DNA methylation though it was not complete. To test directly if this is 
true, we compared methylation patterns in iAsT v. iAs-rev cells. Here too, we still 
observed differential methylation at the sites tested. The gene body had 52% 
hypomethylation and 48% hypermethylation (Figure 3.5D). The TSS1500 exhibited 20% 
hypomethylation and 24% hypermethylation (Figure 3.5D). These findings verify that 
reversal of iAs treatment reversed DNA methylation patterns in gene regulatory regions, 
albeit not completely. 
 In order to better understand the DNA methylation changes occurring in genic 
regions, we performed Venn diagram comparisons of the differentially methylated genes. 
To begin, we compared those genes that are differentially methylated after iAs treatment 
(iAsT v. NT) with those that are differentially methylated after reversal of treatment (iAs-
rev v. NT). The overlapping genes, of which there are 3582, are genes that had more 
permanent changes in methylation (Supplemental Figure 3.3A); our reasoning being that 
these differential methylation patterns are present in both iAsT and iAs-rev cells.  
 Next, we identified those genes whose methylation patterns reversed after removal 
of iAs by comparing genes that were differentially methylated after treatment (iAsT v. NT) 
to those that are differentially methylated between iAs-rev and iAsT cells. This comparison 
resulted in 6825 overlapping genes (Supplemental Figure 3.3B). We consider these genes 
as those with methylation patterns that had reversed to normal conditions because the iAs 
methylation state is similar to NT but different from iAsT cells. This is further confirmed 
by looking at the overlap of genes that were hypomethylated in the iAs-T cells and those 
that were hypermethylated in the iAs-rev. Comparing these groups showed that about 82% 
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of hypomethylated genes in iAsT showed hypermethylation in the iAs-rev (3472 genes of 
4236 total genes), while 71% of genes that were hypermethylated in iAsT showed 
hypomethylation in iAs-rev cells (4103 genes of 5774 total genes) (Supplemental Figure 
3.4). 
 Finally, we compared genes that were differentially methylated in iAs-rev cells to 
those that were differentially methylated between iAs-rev and iAsT cells. There were 4490 
overlapping genes and we interpret these genes as those that are in transition between the 
NT and iAsT methylation state since their methylation state did not remain permanently 
changed but also did not completely revert to normal levels (Supplemental Figure 3.3C). 
 
3.2.7 iAs-mediated DNA methylation changes at promoter associated regions 
Promoter methylation is normally associated with gene repression. Thus, to gain 
insight into the function of iAs-mediated reprogramming of DNA methylation patterns, 
we next focused our analyses of DNA methylation changes at promoter regions. 
Comparing iAsT to NT cells, we observed  a near 50% hypomethylation in promoter-
associated regions, of which 3.71% hypomethylation was associated with cell type specific 
promoter regions (Figure 3.6A, top pie chart). This result is reasonable considering we are 
using the same cell type throughout this study. We next investigated if hypomethylation 
changes in promoter associated regions persisted after reversal of treatment. It seems that 
in iAs-rev cells (iAs-rev v. NT), there was little change – 48.58 % to 49.03%, in promoter-
associated hypomethylation in iAsT cells compared to iAs-rev cells (Figure 3.6A and B, 
top pie charts). This may suggest that hypomethylation in promoter associated regions is 
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stable and permanent and does not revert back to normal conditions upon reversal of iAs 
treatment.  
We next analyzed hypermethylation at promoters. In iAsT cells, there was 38% 
hypermethylation in promoter-associated regions with 3.24% hypermethylation associated 
with cell type specific promoter regions when compared to NT cells (Figure 3.6A, bottom 
pie chart). Interestingly, after withdrawal of iAs treatment (iAs-rev v. NT), there was a 
large increase in hypermethylation at promoter-associated regions (38.16% to 60.66%) 
(Figure 3.6A and B, bottom pie charts). This was also accompanied by a decrease in 
hypermethylation in unclassified regions (25.68% to 19.8%) and unclassified cell type 
specific regions (30.83% to 14.78) (Figure 3.6A and B, bottom pie charts). This shift in 
ratio could suggest that hypermethylation in promoter-associated regions is more 
permanent while hypermethylation in unclassified regions is more transient and able to 
revert back to normal levels after iAs withdrawal. The stark increase in hypermethylation 
at promoter-associated regions is validated by a higher ratio of hypermethylation than 
hypomethylation in that region in the iAs-rev v. iAsT comparison (Figure 3.6C). While 
investigating DNA methylation changes within specific gene regions is advantageous for 
understanding their function, our understanding of DNA methylation in non-promoter 
regions is still in its infancy. In this study, we have focused our attention to promoter and 
gene body methylation at specific genes and the correlation of their methylation status to 
gene expression levels. 
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3.2.8 Coupling of differential methylation and differential gene expression at specific 
loci 
Next, we asked whether these differential methylation patterns affect gene 
expression at the transcript level. DNA methylation at the promoters of genes is typically 
associated with gene repression, and demethylation correlates with increased gene 
expression 172,173. On the other hand, the function of DNA methylation within gene body 
regions is not as definitive. It seems that methylation in the gene body functions in a 
manner opposite to that in the promoter region 185,186. In gene bodies, hypomethylation 
correlates with gene repression while hypermethylation correlates with gene expression 
186. Additionally, DNA methylation in the gene body has been linked to regulation of 
alternative splicing so the full breadth of its function is still poorly understood 116,118,187. 
To examine the impact of DNA methylation changes on gene expression in our 
experimental conditions, RNA was extracted from NT, iAsT and iAs-rev cells. This RNA 
was converted to cDNA and used for quantitative real time PCR analysis (qRT-PCR). For 
this analysis, we chose genes that showed significant differential methylation (Figure 3.3) 
at the promoter region or within the gene body and that could potentially be implicated in 
EMT.  
The first gene examined was CORO1B, which is important in cell motility regulation 
188, and has hypomethylation at the promoter region (Table 3.1). qRT-PCR analysis at the 
transcript level of this gene showed an increase in gene expression in iAsT cells (Figure 
3.7A), correlating with the observed hypomethylation at the promoter region of this gene 
(Table 3.1). The level of gene expression remained high even after iAs was removed (iAs-
rev cells), indicating that this change is more permanent. Interestingly, we were not able 
to identify any significant change in DNA methylation at the promoter of this gene in iAs-
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rev cells, possibly due to the cutoff stringency applied in the differential methylation 
analysis. The second gene we tested was PPME1, which plays a role in malignant glioma 
progression 189. qRT-PCR analysis showed no increase in gene expression in iAsT cells, 
though our genome-wide methylation data indicated this region as being hypermethylated 
(Table 3.1). This could possibly be explained by the fact that not all CpGs regulate gene 
expression. On the other hand, in iAs-rev cells, a significant increase in gene expression 
was observed (Figure 3.7A), We also investigated the PPM1L gene, which is known to 
repress apoptosis 190. Expression levels of this gene were increased in both iAsT and iAs-
rev cells compared to NT cells (Figure 3.7A). These gene expression changes correlated 
positively with the increase in DNA methylation in the gene body of this gene in both iAsT 
and iAs-rev cells compared to NT cells (Table 3.1).  
Five genes exhibited prominent downregulation after iAs treatment (Figure 3.7B). 
For CDH12, expression decreased in iAsT cells and this decrease persisted with iAs-
reversal (Figure 3.7B). CDH12 is a type II classical cadherin protein 191 and the changes 
in its expression correlated with gene body hypomethylation, as well as promoter 
hypermethylation, in iAsT cells compared to NT cells (Figure 3.7B and Table 3.1). The 
decrease in expression from iAsT to iAs-rev also correlates with promoter 
hypermethylation identified in our genome-wide methylation studies. ARID5B, which is 
involved in histone demethylase complexes 192, had a decrease in expression in iAsT cells 
and remained at that level even in iAs-rev cells (Figure 3.7B). This is somewhat surprising 
considering ARID5B has hypomethylation in its promoter region in iAs-rev cells (Table 
3.1). For DYNC1I2, a member of the dynein intermediate chain family 193, a decrease in 
gene expression was observed in iAsT cells compared to NT cells, while iAs removal 
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resulted in upregulation of DYNC1I2 (Figure 3.7B), correlating with the promoter 
hypomethylation observed in the microarray (Table 3.1). PRDX1, a peroxiredoxin family 
member, showed a decrease in expression during iAs treatment correlating with promoter 
hypermethylation in iAsT cells (Figure 3.7B and Table 3.1). After removal of iAs, gene 
expression returned to normal levels (Figure 3.7B). Lastly, gene expression at the EPC1 
gene, a polycomb group member 194, correlated to the observed methylation changes – 
decreased gene expression in iAsT cells compared to NT cells with moderate reversal in 
iAs-rev cells, corresponding with gene body hypomethylation in iAs-rev compared to NT 
cells. So too, an increase in gene expression in iAs-rev cells compared to iAsT cells 
corresponded to the observed hypermethylation at the gene body of the EPC1 gene for 
iAs-rev v. iAsT (Figure 3.7B).  
The fact that expression of some genes such as PPM1L, DYNC1I2, PRDX1, and 
EPC1 reverted to normal levels in iAs-rev and that those gene expression changes correlate 
to reversal of DNA methylation patterns suggests the role of epigenetics in this process. 
However, other changes instigated by iAs treatment were more permanent, such as the 
gene expression changes seen for CORO1B, PPME1, CDH12, and ARID5B and suggest 
that either these epigenetic factors were not reversed within the time frame allowed or that 
other factors together with epigenetics are stabilizing a more permanently changed gene 
expression state of the gene.  
 
3.2.9 Global correlation of gene expression patterns with DNA methylation patterns 
In order to further understand the biological significance of differential methylation 
in iAsT and iAs-rev cells, we examined the overlap of genes that were both differentially 
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methylated as well as differentially expressed at the transcript level. For this analysis we 
reanalyzed our previous dataset (GSE60760) of iAs-mediated differentially expressed 
genes 124. To understand the pathways targeted in iAsT, we analyzed the overlap between 
genes differentially expressed in iAsT cells and those differentially methylated in iAsT 
cells. There were 270 genes that were both differentially methylated and differentially 
expressed in cells treated with inorganic arsenic (Supplemental Figure 3.5A).  For the sake 
of simplicity, Venn diagram analysis was performed on all genes that were differentially 
expressed as well as differentially methylated.  
We then performed gene ontology (GO) analyses using the Gene Set Enrichment 
Analysis (GSEA) to identify regulatory pathways affected by both differential methylation 
and differential expression. Our analyses show that signal transduction pathways and 
development processes are enriched, indicating that these pathways are targeted by iAs 
(Table 3.2). Since we observed that iAsT cells were undergoing EMT, we analyzed the 
target genes for oncogenic signatures. Our analysis showed that some of the genes with 
differential methylation and differential gene expression are involved in abnormal 
expression of K-RAS (an oncogene) in epithelial cells, particularly lung, breast, and kidney 
tissue (Supplemental Table 3.1). 
We next asked if these pathways are still targeted in iAs-rev cells. We identified 187 
genes that are both differentially methylated and differentially expressed in iAs-rev cells 
(Supplemental Figure 3.5B). These genes represent those whose methylation patterns did 
not revert to normal levels and  therefore appeared to be permanently changed. GO analysis 
of these genes showed enrichment in biological processes such as development and 
metabolic processes (Table 3.3). Investigating the oncogenic signature of these genes also 
55 
 
revealed that they are involved in abnormal expression of K-RAS in lung, breast, and 
kidney epithelial tissue, similarly to iAsT cells (Supplemental Table 3.2). This could 
indicate that while some genes are reverting back to normal levels of expression, the genes 
that do not revert are driving the carcinogenic potential of iAs treatment.  
Finally, we investigated those genes that are differentially methylated between iAs-
rev cells and iAsT cells. These genes represent the group of genes that are transient and 
return to a more normalized condition after iAs removal (Supplemental Figure 3.5C). GO 
analysis of these genes revealed enrichment in biological processes such as signal 
transduction, metabolism, and cell death (Table 3.4). Their oncogenic signatures again 
showed dysregulation of K-RAS in epithelial cells in lung, kidney, and breast tissue 
(Supplemental Table 3.3). A complete gene ontology listing of these genes with regards to 
their hyper- and hypomethylation state is found in Supplemental Tables 3.4-3.6. 
In summary, we show that differential methylation correlates with differential 
expression, both during treatment and after the reversal of treatment. While some 
differential methylation and differential expression changes remained after reversal of 
treatment, others reversed back to normal conditions. Since the breadth of the impact of 
methylation is not completely known, we also observed that some methylation patterns 
which were reversed did not correlate with changes in gene expression. Additionally, it 
seems that even though some genes are reversed, the cells are still poised in an oncogenic 
state, as revealed by the oncogenic signatures. However, our data provides a platform 
enabling the probing of DNA methylation patterns, reversal of those patterns, and the 
function either in promoting direct gene expression and/or in the possible recruitment of 
factors that might aid in gene expression. This is especially intriguing as we observed that 
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the K-RAS regulatory process might be specifically targeted by iAs in disease 
pathogenesis. 
 
 Discussion 
To date, few studies have identified specific gene loci that are differentially 
methylated in response to chronic iAs exposure. The dose used in our experiments is 
biologically relevant and mimics the dosage many living in mining regions are exposed to 
daily 1,2,181. Sadly, in some countries, people are exposed to even higher amounts on a 
regular basis 156,177,195. Ours is the first study to distinguish between permanent and 
reversible DNA methylation changes using data from cells with treatment reversal. The 
treatment group that experienced reversal of treatment is also biologically relevant as it 
imitates the case in which people move away from an area that has chronic low dose 
arsenic exposure, quit smoking, or otherwise remove themselves from environments where 
they are experiencing high levels of inorganic arsenic. All of these situations happen 
frequently and while these people experience a cessation of exposure, the biologic effects 
may still persist, as shown by this study.  
Our studies show that chronic low-dose exposure to iAs leads to global methylation 
changes (Figures 3.2 and 3.3) as well as differential methylation in gene regulatory regions 
(Figures 3.4-3.6) and specific genes (Table 3.1). Differential methylation is concentrated 
to CGIs (Figure 3.4), upstream promoter regions, and gene bodies (Figure 3.5). The 
differential methylation correlates to changes in gene expression which may be a driving 
factor in the epithelial-to-mesenchymal transition (Figure 3.1 and 3.7). Upon reversal of 
treatment, some methylation and expression changes revert to normal conditions and 
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others do not (Figure 3.7 and Table 3.1). Ontology analysis of genes targeted in iAs-
mediated differential methylation patterns revealed an enrichment of cellular processes, 
such as cell signaling and development, after initial iAs exposure and enrichment of 
processes involved in metabolism after iAs withdrawal (Tables 3.2-3.4).  
Our study is unique in its investigation of biological consequences of removal of iAs 
exposure. The initial insult of chronic low dose exposure to iAs is clearly detrimental due 
to its ability to cause cellular transformation and EMT 63,124,174. However, the ramifications 
of iAs exposure do not fully disappear when exposure ends. It appears that while some 
changes partially revert back to normal conditions after exposure is removed, many 
changes remain in their abnormal state (Figure 3.1). Previous studies showed this partial 
reversal in morphology, gene expression and protein levels of EMT markers, DNA 
methylation patterns, and gene expression patterns 63,124,174. What we are showing now is 
methylation and gene expression changes due to withdrawal of iAs exposure. For DNA 
methylation and its effect on gene expression, we hypothesize that the genes that remain 
differentially methylated and expressed, such as CORO1B and CDH12, are driving 
transformation and EMT, while those that revert back to normal levels of methylation and 
expression, such as DYNC1I2 and EPC1, are involved in early adaptation to iAs exposure 
and are less involved in transformation and EMT. Additional studies will be needed to 
identify specific genes as drivers or passengers. By identifying specific genes that are 
differentially methylated between iAsT and its withdrawal, we can parse out which genes 
are still altered after reversal and which revert to a more normal phenotype. We 
hypothesize that as cells undergo iAs-mediated EMT, hypomethylation may be occurring 
at oncogenes while hypermethylation may be occurring at tumor suppressors.  
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We are also intrigued and encouraged by the fact that our previous studies in BEAS-
2B cells and our current study in HeLa cells show similar results in EMT markers, DNA 
methylation patterns, and carcinogenic potential 63,124,174. This finding indicates that HeLa 
cells can be used as an effective model for chronic low-dose iAs-mediated epithelial-to-
mesenchymal transition. We witnessed similar changes in cell morphology expression and 
protein levels of EMT markers in both cell types. Additionally, we found that DNA 
methylation correlates to changes in gene expression patterns that contribute to EMT for 
both cell types. Furthermore, HeLa cells and BEAS-2B cells returned similar gene 
ontology results for pathways and processes that are being targeted in iAs treatment such 
as cell signaling and neurogenesis (Tables 3.2-3.4) 174. As would be expected, there were 
some minor differences between the results we observed in HeLa cells compared to BEAS-
2B cells. For example, BEAS-2B cells had slight global hypomethylation while HeLa cells 
had slight global hypermethylation upon treatment 174. Differences could be due to the 
state of the cells used in the experiments. In our earlier studies, we used non-carcinogenic 
cells, whereas in this study, HeLa cells are already carcinogenic. Even though one cell line 
is carcinogenic and the other is not, iAs caused EMT in both and we believe that similar 
mechanisms are driving EMT in both cell lines. Transformation and carcinogenesis are 
dynamic processes that rely on several mechanisms, EMT being one of them. It seems that 
in HeLa cells, iAs treatment pushes EMT even further. It would be interesting to compare 
the changes seen in BEAS-2B and HeLa to determine which changes are contributing to 
cellular transformation and which are contributing to EMT. 
For the most part, our expression data matched what we would expect based on the 
methylation present in the gene (Figure 3.7). However, a few genes, such as PPME1, 
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exhibited expression changes that were opposite of what we would expect due to the 
methylation data. One explanation is that not every CpG is able to influence gene 
expression with its methylation status; some CpGs are regulatory and others are not. With 
so much data, it’s possible that not every CpG is regulatory. Some CpGs could be 
functioning as a location for other transcription factors or proteins to bind that may have 
functions other than mediating gene expression 118,196. For many of the genes we 
investigated, there was differential methylation in several regions. In our data set, some 
genes had antagonistic methylation changes such as hypomethylation at one CpG in the 
promoter and hypermethylation at another CpG in the same promoter. It’s been proposed 
that methylation may function differently depending on whether it’s in an intron or exon 
187. Further research is needed to answer these questions and to understand the full function 
of gene body methylation in the context of low dose arsenic exposure. Clearly, we are at 
the beginning of understanding the full function of DNA methylation. Interestingly, recent 
studies have linked methylation changes to alterations in alternative splicing patterns 
116,118,187. Our own previous studies implicated all of the genes from our gene expression 
experiment as having alternative splicing changes (Supplemental Table 3.7).  
The vastness of the data we gained from the Infinium MethylationEPIC BeadChip 
Array underscores the complexity of differential DNA methylation in cells, and therefore 
the depth of our understanding. For instance, tens of thousands of loci are differentially 
methylated in response to low dose arsenic exposure and/or reversal of treatment (Figure 
3.3 and Supplemental Figure 3.1); which of them is actually regulatory is the subject of 
additional study. However, inorganic arsenic is known to cause detrimental effects through 
mechanisms other than epigenetics, such as reactive oxygen species 10,11,197. It is also 
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possible that both mechanisms are working together, enhancing biologic actions to drive 
the carcinogenic potential of iAs 198,199. Further studies to understand this cooperation 
would be interesting. In addition to ROS, DNA methylation is also known to interplay 
with other epigenetic modifications such histone variants and histone post-translational 
modifications 37,63,124. Because other epigenetic marks are altered in iAs-mediated EMT, 
it is plausible that they all work collectively. For example, dysregulation of histones H2B 
and H3 has been implicated in iAs-mediated transformation and EMT 63,76. Additionally, 
alterations in histone post-translational modifications have been shown in iAs-treated 
conditions including upregulation of the repressive mark H3K27me3 and activation of the 
mark H3K4me3. It is hypothesized that crosstalk between all of these epigenetic marks – 
DNA methylation, histone variants, and histone post-translational modifications – control 
the chromatin landscape present in iAs treated cells. For example, DNA methylation and 
H3K27me3 are known to be coregulated and both dynamically monitor DNA accessibility 
and gene expression 200,201. Therefore, the full implications of iAs exposure cannot fully 
be appreciated without understanding the crosstalk between epigenetic marks. 
In conclusion, this study presents genome-wide changes to DNA methylation levels, 
as well as changes in gene expression in HeLa cells that were exposed to iAs at chronic 
low-dose levels, and also in cells that had the arsenic removed. We found that in many 
cases, the changes seen in cells exposed to iAs returned to near NT levels; these regions 
may be important in the cellular response to the iAs. However, many genes either do not 
revert to NT levels, or show an increased change in DNA methylation and gene expression. 
These genes may be involved in the EMT process that drives the carcinogenic effects with 
chronic low-dose iAs exposure. Our results provide a platform to develop potential 
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epigenetic therapeutics in iAs-mediated carcinogenesis. Such studies could be extended to 
other environmental toxicants to enhance the understanding of their impact on the 
epigenome and gene expression. 
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Table 3.1 Expected methylation patterns for genes investigated for gene expression. 
 
  
Gene 
Region iAsT Methylation 
iAsT Expected 
Expression 
iAs-rev 
Methylation 
iAsT Expected 
Expression 
CORO1B Promoter Hypomethylation Upregulated NA NA 
PPME1 Promoter Hypermethylation Downregulated NA NA 
PPM1L Gene Body Hypermethylation Upregulated Hypermethylation Upregulated 
CDH12 Gene Body Hypomethylation Downregulated NA NA 
ARID5B Promoter NA NA Hypomethylation Upregulated 
DYNC1I2 Promoter NA NA Hypomethylation Upregulated 
PRDX1 Promoter Hypermethylation Downregulated Hypermethylation Downregulated 
EPC1 Gene Body NA NA Hypomethylation Downregulated 
 
Methylation patterns identified by the Infinium BeadChip Microarray for each gene that 
was investigated for gene expression changes by qRT-PCR; the expected gene expression 
patterns based on methylation are presented. Shaded cells indicate that the expected 
expression was validated by our qRT-PCR results. 
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Table 3.2 Gene Ontology of differentially methylated and differentially expressed genes 
(iAsT v. NT). 
 
GO Term Number of Genes p-value 
Intracellular Signal Transduction 36 3.05E-13 
Intrinsic Component of Plasma Membrane 36 1.22E-12 
Receptor Binding 32 2.93E-11 
Cell Development 31 5.74E-11 
Tissue Development 32 5.97E-11 
Movement of Cell or Subcellular 
Component 29 8.81E-11 
Regulation of Cell Death 30 5.52E-10 
Response to Endogenous Stimulus 29 1.67E-09 
Negative Regulation of Response to 
Stimulus 28 1.74E-09 
Protein Phosphorylation 23 2.43E-09 
 
Gene Ontology terms of differentially methylated and differentially expressed genes 
comparing iAsT to NT (270 total genes). 
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Table 3.3 Gene Ontology of differentially methylated and differentially expressed genes 
(iAs-rev v. NT). 
 
GO Term Number of Genes p-value 
Intrinsic Component of Plasma Membrane 32 3.90E-14 
Cell Development 23 7.07E-09 
Response to Oxygen Containing Compound 22 1.92E-08 
Small Molecule Metabolic Process 25 1.96E-08 
Response to Nitrogen Compound 17 4.21E-08 
Tissue Development 22 9.99E-08 
Neuron Part 20 1.01E-07 
Cell Junction 19 1.11E-07 
Cytoskeleton 25 1.52E-07 
Response to Endogenous Stimulus 21 2.02E-07 
 
Gene Ontology terms of differentially methylated and differentially expressed genes 
comparing iAs-rev to NT (187 total genes). 
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Table 3.4 Gene Ontology of differentially methylated and differentially expressed genes 
(iAs-rev v. iAsT). 
 
GO Term 
Number of 
Genes p-value 
Intrinsic Component of Plasma Membrane 46 5.76E-17 
Receptor Binding  38 4.46E-13 
Intracellular Signal Transduction 39 6.68E-13 
Regulation of Cell Death 36 8.35E-12 
Phosphate Containing Compound Metabolic Process 42 1.18E-11 
Negative Regulation of Cell Death 27 2.35E-11 
Response to Endogenous Stimulus 35 2.39E-11 
Response to Oxygen Containing Compound 34 2.79E-11 
Biological Adhesion 29 4.15E-11 
Neurogenesis 34 4.16E-11 
 
Gene Ontology terms of differentially methylated and differentially expressed genes 
comparing iAs-rev to iAsT (322 total genes). 
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Figure 3.1 Chronic low-dose exposure to iAs and subsequent reversal causes cells to 
undergo EMT. 
 
 
 
(A). Diagram of Experimental Design. HeLa cells were treated with 0.5µM sodium 
arsenite (iAsT) while some were mock treated with dIH2O (NT). After 36 days of iAs 
treatment, sodium arsenite was removed from growth media for some treated cells and 
replaced with dIH2O (iAs-rev); (B). Western blot analysis of EMT markers show HeLa 
cells undergoing iAs-induced EMT. Claudin-1 decreased with treatment, and remained 
decreased in the iAs-rev condition. Some markers, like Snail, increased in the iAsT, but 
did not return toward NT levels in iAs-rev cells while N-cadherin and Slug increased in 
iAsT and returned toward NT levels. 
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Figure 3.2 Global DNA methylation levels are increased with 0.5 µM arsenite exposure. 
 
 
 
 
Results from the 5mC-ELISA show that 0.5µM sodium arsenite exposure significantly 
increased global DNA methylation levels in HeLa cells. iAsT cells that had exposure 
removed (iAs-rev) showed a significant decrease from the iAsT DNA methylation levels; 
however, these are still significantly increased from NT levels. ELISA was performed in 
triplicate and error bars reflect the SEM of these replicates. Students t-test was performed 
for significance (p<0.05); * denotes difference from NT † denotes difference from iAsT 
to iAs-rev.  
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Figure 3.3 Methylation EPIC BeadChip Assay reveals global DNA methylation changes 
between NT, iAsT, and iAs-rev. 
 
 
 
Comparison of loci from NT v. iAsT shows that 67% of loci on the chip are 
hypermethylated in iAsT, while only 33% are hypomethylated.  Comparison of 
methylation loci between NT and iAs-rev shows that 77% of loci are hypermethylated in 
iAs-rev while only 23% are hypomethylated.  Comparison of iAsT and iAs-rev reveals 
that the loci are approximately equal for hyper- and hypomethylation, suggesting that when 
iAs is removed many loci return towards NT levels. 
 
  
69 
 
Figure 3.4 DNA methylation patterns show changes both within CGIs and outside of 
CGIs during iAs-mediated EMT. 
 
 
 
(A). Diagram showing the relationship of CGIs and neighboring regions. CGI is defined 
as greater than 50% CG content in at least a 200 base pair region. The north shore is 0-
2000bp upstream of the CGI and north shelf is 2001-4000bp upstream of the CGI. The 
south shore is 0-2000bp downstream of the CGI and the south shelf is 2001-4000bp 
downstream of the CGI. Open sea regions are more than 4000bp outside of the CGI. (B). 
Regional methylation changes between iAsT v. NT (C). Regional methylation changes 
between iAs-rev v. NT (D). Regional methylation changes between iAs-rev v. iAsT. 
Levels of methylation in shelves and shores stay relatively unchanged between groups and 
hyper- or hypomethylation. Prominent methylation changes occur at the CGIs and out in 
the open seas. 
 
  
70 
 
Figure 3.5 DNA methylation patterns within gene regulatory regions reveal large changes 
within gene bodies, at the 1st exon, and 200-1500bp upstream of start of transcription. 
 
 
 
(A). Diagram mapping gene regulatory regions. TSS1500 is 200-1500bp upstream of 
transcription start site (TSS), TSS200 is 1-200bp upstream of TSS, 5’UTR is the 5’ 
untranslated region, 1st exon is the first translated region, gene body includes all other 
exons and all introns, and 3’UTR is the 3’ untranslated region where translation ends. 
Outside of the TSS1500 and 3’UTR is considered intergenic. (B). Gene Regulatory 
methylation differences between iAsT and NT. (C). Gene Regulatory methylation 
differences between iAs-rev and NT. (D). Gene Regulatory methylation differences 
between iAs-rev and iAsT. Methylation within gene regulatory regions is generally stable 
throughout the treatment groups. Gene body and TSS1500 methylation shows the most 
variation between hyper- and hypomethylated DMRs. 
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Figure 3.6 DNA methylation level changes at promoter associated regions reveal large 
changes within the promoter and unclassified regions. 
 
 
 
Comparison of DMRs within different promoter types. (A). Regional promoter-associated 
methylation differences between iAsT and NT. (B). Regional promoter-associated 
methylation differences between iAs-rev and NT. (C). Regional promoter-associated 
methylation differences between iAs-rev and iAsT. Promoter methylation changes are 
most apparent at promoter associated (dark green) and unclassified regions (purple), which 
suggests that iAs targets distinct promoters and regions in methylation changes. 
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Figure 3.7 Correlation of differential methylation and gene expression. 
 
 
 
 
(A). Three genes were upregulated with iAs treatment. CORO1B and PPME1 both 
increased in expression with iAsT and a further increase was observed in iAs-rev. PPM1L 
increased in iAsT, but shifted towards NT levels with iAs-rev. (B). Seven genes were 
downregulated with iAs treatment. CDH12 and ARID5B decreased expression levels with 
iAsT as well as with iAs-rev. DYNC12, PRDX1 and EPC1 all decreased expression levels 
with iAsT, but with iAs-rev the expression levels increased closer to or even above NT 
levels. qRT-PCR reactions were performed in triplicate. * indicates a significant change 
when iAsT or iAs-rev is compared to NT and † indicates a significant change between 
iAsT and iAs-rev with p-value <0.05. Error bars are from triplicate experiments and 
represent SEM. 
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Supp. Table 3.1 Oncogenic signature of top 4000 DMRs (iAsT v. NT). List of oncogenic 
signatures identified for the top 4000 differentially methylated genes for iAsT v. NT. 
 
Description 
# Genes 
in 
Overlap 
(k) p-value 
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 22 4.23E-13 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 29 3.49E-12 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] gene. 22 6.25E-10 
Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176]. 21 5.68E-09 
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an 
oncogenic form of KRAS [Gene ID=3845] gene. 24 1.27E-08 
Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of TP53 [Gene 
ID=7157] gene by RNAi. 17 4.51E-08 
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 23 5.55E-08 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 16 7.71E-08 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene 
ID=7703] gene by RNAi. 16 9.33E-08 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-
7 cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene. 19 1.37E-07 
Genes up-regulated in neurons. 13 1.71E-07 
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 16 2.59E-07 
Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem = 
6610346]. 17 3.40E-07 
Genes down-regulated in MEF cells (embryonic fibroblasts) with knockout of SNF5 [Gene 
ID=6598] gene. 16 3.85E-07 
Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene 
ID=4780] gene. 29 4.48E-07 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 21 8.73E-07 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 22 1.04E-06 
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway 
activation by thyrotropin (TSH). 17 1.18E-06 
Genes down-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene 
ID=51176]. 17 2.16E-06 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and 
PCGF2 [Gene ID=648, 7703] genes by RNAi. 14 2.71E-06 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] 
gene. 16 3.13E-06 
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by 
RNAi. 20 3.32E-06 
Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene 
ID=5281]. 16 3.58E-06 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-
7 cells (breast cancer) and long-term adapted for estrogen-independent growth. 16 4.09E-06 
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an 
oncogenic form of KRAS [Gene ID=3845] gene. 21 4.21E-06 
Genes down-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene 
ID=5728] by RNAi. 14 6.45E-06 
Genes down-regulated in epithelial lung cancer cell lines over-expressing KRAS [Gene 
ID=3845] gene. 14 7.56E-06 
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2 
[Gene ID=1386] gene. 16 7.57E-06 
Genes down-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene. 16 7.57E-06 
Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717] 
gene by RNAi. 16 8.11E-06 
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Genes up-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 13 8.71E-06 
Genes up-regulated in A549 lung carcinoma and M059K glioblastoma cells treated with 
dichloroacetate [PubChem=6597]. 16 9.90E-06 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable ERBB2 [Gene ID=2064]. 16 9.90E-06 
Genes down-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene. 15 1.00E-05 
Genes down-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157]. 16 1.06E-05 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene 
ID=648] gene by RNAi. 13 1.09E-05 
Genes down-regulated in epithelial prostate cancer cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 13 1.09E-05 
Genes down-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene. 16 1.13E-05 
Genes up-regulated in MOLM-14 cells (AML) with knockdown of HOXA9 [Gene ID=3205] 
gene by RNAi vs controls. 16 1.20E-05 
Genes up-regulated upon knockdown of PTEN [Gene ID=5728] by RNAi. 15 1.29E-05 
Genes up-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic 
form of KRAS [Gene ID=3845] gene and knockdown of TBK1 [Gene ID=29110] gene by 
RNAi. 19 1.32E-05 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of EED [Gene ID=8726] gene. 15 1.55E-05 
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=] 
stimulation after pre-treatment with the ERK inhibitors U0126 and PD98059 
[PubChem=3006531, 4713]. 13 1.58E-05 
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway 
activation by thyrotropin (TSH). 16 1.76E-05 
Genes up-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 13 2.41E-05 
Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 
[Gene ID=648, 7703] genes by RNAi. 13 3.25E-05 
Genes down-regulated in epithelial breast cancer cell lines over-expressing an oncogenic form 
of  KRAS [Gene ID=3845] gene. 13 3.25E-05 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 13 3.49E-05 
Genes up-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene. 15 3.50E-05 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL21 [Gene ID=59067]. 14 4.22E-05 
Genes down-regulated upon knockdown of PTEN [Gene ID=5728] by RNAi. 14 4.22E-05 
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 19 4.72E-05 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512] 
gene. 15 4.73E-05 
Genes up-regulated in epithelial prostate cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 12 4.88E-05 
Genes up-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene 
ID=5728] by RNAi. 12 4.88E-05 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] 
gene. 15 5.32E-05 
Genes down-regulated in retina cells from CRX [Gene ID=1406] knockout mice. 12 6.53E-05 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of ALK [Gene 
ID=238] gene by RNAi. 12 6.82E-05 
Genes up-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts). 13 7.11E-05 
Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem = 
6610346]. 14 9.37E-05 
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 12 1.22E-04 
Genes up-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of 
CCND1 [Gene ID=595] gene. 14 1.39E-04 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 12 1.39E-04 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 18 1.40E-04 
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Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281]. 14 1.47E-04 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512] 
gene. 14 1.47E-04 
Genes up-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes. 14 1.56E-04 
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2 
[Gene ID=1386] gene. 13 1.65E-04 
Genes up-regulated during early stages of differentiation of embryoid bodies from V6.5 
embryonic stem cells. 13 1.65E-04 
Genes down-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975] 
by RNAi. 18 1.66E-04 
Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene 
ID=5281]. 14 1.73E-04 
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene 
ID=672] gene by RNAi. 11 1.90E-04 
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of RBBP8 [Gene 
ID=RBBP8] gene by RNAi. 11 1.90E-04 
Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of RELA [Gene 
ID=5970] gene by RNAi. 11 1.90E-04 
Genes up-regulated in CEM-C1 cells (T-CLL) by rapamycin (sirolimus) [PubChem = 
6610346], an mTOR pathway inhibitor. 14 1.93E-04 
Genes up-regulated during late stages of differentiation of embryoid bodies from J1 embryonic 
stem cells. 13 2.03E-04 
Genes down-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem = 
6610346]. 13 2.03E-04 
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of 
NOTCH signaling pathway. 13 2.25E-04 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512] 
gene. 13 2.37E-04 
Genes up-regulated in primary thyrocyte cultures in response to cAMP signaling pathway 
activation by thyrotropin (TSH). 14 2.38E-04 
Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 
[Gene ID=648, 7703] genes by RNAi. 11 2.43E-04 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 11 2.43E-04 
Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176]. 13 2.49E-04 
Genes up-regulated during early stages of differentiation of embryoid bodies from V6.5 
embryonic stem cells. 12 2.52E-04 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable EGFR [Gene ID=1956]. 13 2.61E-04 
Genes up-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene 
ID=7422]. 13 2.61E-04 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable ERBB2 [Gene ID=2064]. 13 2.75E-04 
Genes up-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue 
transgenically expressing human AKT1 gene [Gene ID=207]  vs untreated controls. 13 3.58E-04 
Genes down-regulated during late stages of differentiation of embryoid bodies from J1 
embryonic stem cells. 13 3.97E-04 
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by 
RNAi. 17 4.10E-04 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL21 [Gene ID=59067]. 13 4.18E-04 
Genes down-regulated in CD34+ hematopoietic progenitor cells after knockdown of RPS14 
[Gene ID=6208] by RNAi. 13 4.18E-04 
Genes up-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic 
form of KRAS [Gene ID=3845] gene and knockdown of TBK1 [Gene ID=29110] gene by 
RNAi. 17 4.44E-04 
Genes up-regulated during late stages of differentiation of embryoid bodies from J1 embryonic 
stem cells. 13 5.11E-04 
Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5 
embryonic stem cells. 12 6.88E-04 
Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281]. 12 7.20E-04 
Genes down-regulated in CEM-C1 cells (T-CLL) by rapamycin (sirolimus) [PubChem = 
6610346], an mTOR pathway inhibitor. 12 7.89E-04 
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=] 
stimulation. 10 8.22E-04 
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Supp. Table 3.2 Oncogenic signature of top 4000 DMRs (iAs-rev v. NT). List of 
oncogenic signatures identified for the top 4000 differentially methylated genes for iAs-
rev v. NT. 
 
Description 
# Genes 
in 
Overlap 
(k) p-value 
Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem = 6610346]. 23 7.27E-11 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene. 24 2.45E-10 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 26 5.74E-09 
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 18 1.01E-08 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 18 1.12E-08 
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway 
activation by thyrotropin (TSH). 21 1.27E-08 
Genes up-regulated by everolimus [PubChem = 6442177] in prostate tissue. 19 9.24E-08 
Genes down-regulated during early stages of differentiation of embryoid bodies from V6.5 
embryonic stem cells. 18 1.44E-07 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 25 1.46E-07 
Genes down-regulated in NOMO-1 and SKM-1 cells (AML) after knockdown of STK33 [Gene 
ID=65975] by RNAi. 25 1.56E-07 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512] 
gene. 19 1.87E-07 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable EGFR [Gene ID=1956]. 20 1.93E-07 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene. 20 1.93E-07 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable ERBB2 [Gene ID=2064]. 20 2.10E-07 
Genes up-regulated in neurons. 14 2.82E-07 
Genes down-regulated in MEF cells (embryonic fibroblasts) with knockout of SNF5 [Gene 
ID=6598] gene. 17 3.64E-07 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 
[Gene ID=648, 7703] genes by RNAi. 16 4.11E-07 
Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene 
ID=4780] gene. 31 5.37E-07 
Genes up-regulated during late stages of differentiation of embryoid bodies from J1 embryonic 
stem cells. 19 5.74E-07 
Genes up-regulated in neurons. 13 6.48E-07 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146] gene. 19 7.89E-07 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene. 19 8.52E-07 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 16 1.12E-06 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene 
ID=7703] gene by RNAi. 16 1.47E-06 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 22 1.54E-06 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 23 1.81E-06 
Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281]. 18 2.46E-06 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512] 
gene. 18 3.07E-06 
Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176]. 18 3.31E-06 
Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene 
ID=4780] gene. 31 3.46E-06 
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Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146] 
gene. 17 3.78E-06 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene 
ID=648] gene by RNAi. 15 4.92E-06 
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 15 5.35E-06 
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by 
RNAi. 21 5.47E-06 
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an 
oncogenic form of KRAS [Gene ID=3845] gene. 21 5.77E-06 
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene 
ID=672] gene by RNAi. 14 6.37E-06 
Genes up-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by 
RNAi. 22 7.26E-06 
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2 
[Gene ID=1386] gene. 17 7.53E-06 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 14 8.81E-06 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable ERBB2 [Gene ID=2064]. 17 9.96E-06 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable EGFR [Gene ID=1956]. 17 1.14E-05 
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595] 
gene. 16 1.28E-05 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] 
gene. 16 1.36E-05 
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of 
NOTCH signaling pathway. 16 1.45E-05 
Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281]. 16 1.55E-05 
Genes up-regulated in primary keratinocytes from RB1 and RBL1 [Gene ID=5925, 5933] skin 
specific knockout mice. 14 1.61E-05 
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by 
RNAi. 21 2.10E-05 
Genes down-regulated during early stages of differentiation of embryoid bodies from J1 
embryonic stem cells. 15 2.35E-05 
Genes up-regulated in NOMO-1 and SKM-1 cells (AML) after knockdown of STK33 [Gene 
ID=65975] by RNAi. 21 2.71E-05 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 
[Gene ID=648, 7703] genes by RNAi. 14 2.79E-05 
Genes up-regulated in granule cell neuron precursors (GCNPs) after stimulation with Shh for 
24h. 15 3.04E-05 
Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717] 
gene by RNAi. 16 3.13E-05 
Genes down-regulated in granule cell neuron precursors (GCNPs) after stimulation with Shh for 
3h. 15 3.36E-05 
Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5 embryonic 
stem cells. 16 3.56E-05 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene 
ID=648] gene by RNAi. 13 3.73E-05 
Genes down-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes. 16 3.79E-05 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] 
gene. 16 4.04E-05 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene 
ID=7703] gene by RNAi. 13 4.96E-05 
Genes up-regulated in primary epithelial breast cancer cell culture over-expressing E2F3 [Gene 
ID=1871] gene. 16 5.18E-05 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) and long-term adapted for estrogen-independent growth. 16 5.18E-05 
Genes up-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene. 15 5.29E-05 
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of 
CCND1 [Gene ID=595] gene. 15 5.96E-05 
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 19 6.19E-05 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) and long-term adapted for estrogen-independent growth. 15 6.69E-05 
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Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 20 6.79E-05 
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene 
ID=672] gene by RNAi. 13 7.47E-05 
Genes down-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975] 
by RNAi. 20 7.82E-05 
Genes up-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by 
RNAi. 20 8.58E-05 
Genes up-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue transgenically 
expressing human AKT1 gene [Gene ID=207]  vs untreated controls. 15 8.92E-05 
Genes down-regulated during late stages of differentiation of embryoid bodies from J1 
embryonic stem cells. 15 1.01E-04 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL21 [Gene ID=59067]. 15 1.07E-04 
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of RBBP8 [Gene 
ID=RBBP8] gene by RNAi. 12 1.29E-04 
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595] 
gene. 15 1.35E-04 
Genes up-regulated in early serum response of CRL 2091 cells (foreskin fibroblasts). 13 1.41E-04 
Genes up-regulated in CD34+ hematopoietic progenitor cells after knockdown of RPS14 [Gene 
ID=6208] by RNAi. 15 1.43E-04 
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene 
ID=672] gene by RNAi. 12 1.48E-04 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of EED [Gene ID=8726] 
gene. 15 1.52E-04 
Genes up-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts). 14 1.54E-04 
Genes up-regulated in MOLM-14 cells (AML) with knockdown of HOXA9 [Gene ID=3205] 
gene by RNAi vs controls. 15 1.61E-04 
Genes up-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157]. 15 1.61E-04 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL2 [Gene ID=3558]. 15 1.80E-04 
Genes down-regulated in NOMO-1 and SKM-1 cells (AML) after knockdown of STK33 [Gene 
ID=65975] by RNAi. 18 1.88E-04 
Genes down-regulated in a panel of epithelial cell lines by TGFB1 [Gene ID=7040]. 14 1.92E-04 
Genes up-regulated in myometrial cells over-expressing a shortened splice form of ATF2 [Gene 
ID=1386] gene. 14 2.03E-04 
Genes down-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene. 14 2.03E-04 
Genes down-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975] 
by RNAi. 18 2.13E-04 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable EGFR [Gene ID=1956]. 14 2.38E-04 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene. 14 2.38E-04 
Genes up-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene ID=7422]. 14 2.38E-04 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable ERBB2 [Gene ID=2064]. 14 2.51E-04 
Genes up-regulated in primary keratinocytes from RB1 [Gene ID=5925] skin specific knockout 
mice. 11 4.03E-04 
Genes down-regulated in mouse prostate by transgenic expression of human AKT1 gene [Gene 
ID=207]  vs controls. 13 5.07E-04 
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2 
[Gene ID=1386] gene. 13 5.07E-04 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL21 [Gene ID=59067]. 13 5.07E-04 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) and long-term adapted for estrogen-independent growth. 13 5.89E-04 
Genes up-regulated in epithelial lung cancer cell lines over-expressing KRAS [Gene ID=3845] 
gene. 11 6.15E-04 
Genes down-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157]. 13 6.50E-04 
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Supp. Table 3.3 Oncogenic signature of top 4000 DMRs (iAs-rev v. iAsT). List of 
oncogenic signatures identified for the top 4000 differentially methylated genes for iAs-
rev v. iAsT. 
 
Description 
# Genes 
in 
Overlap 
(k) p-value 
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 21 3.08E-13 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 24 8.91E-10 
Genes up-regulated in neurons. 14 4.32E-09 
Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of TP53 [Gene 
ID=7157] gene by RNAi. 18 7.35E-09 
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 17 4.51E-08 
Genes down-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene. 17 7.45E-08 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene. 17 1.47E-07 
Genes up-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene 
ID=5728] by RNAi. 14 4.22E-07 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] gene. 18 4.75E-07 
Genes down-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes. 16 5.45E-07 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146] 
gene. 18 6.46E-07 
Genes up-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene 
ID=5728] by RNAi. 15 1.17E-06 
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 19 1.89E-06 
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene 
ID=672] gene by RNAi. 13 2.14E-06 
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of 
NOTCH signaling pathway. 17 2.68E-06 
Genes down-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 13 2.93E-06 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable EGFR [Gene ID=1956]. 15 3.12E-06 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene. 17 3.31E-06 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 
[Gene ID=648, 7703] genes by RNAi. 13 3.41E-06 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene 
ID=7703] gene by RNAi. 13 3.68E-06 
Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem = 6610346]. 16 5.75E-06 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 14 7.56E-06 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of ALK [Gene 
ID=238] gene by RNAi. 14 8.85E-06 
Genes down-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts). 15 1.00E-05 
Genes down-regulated in retina cells from CRX and NRL [Gene ID=1406, 4901] double 
knockout mice. 13 1.01E-05 
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2 
[Gene ID=1386] gene. 14 1.01E-05 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable EGFR [Gene ID=1956]. 16 1.13E-05 
Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281]. 16 1.20E-05 
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512] 
gene. 16 1.20E-05 
Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5 embryonic 
stem cells. 14 1.21E-05 
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Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146] gene. 16 1.28E-05 
Genes up-regulated upon knockdown of PTEN [Gene ID=5728] by RNAi. 14 1.29E-05 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 20 1.31E-05 
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of 
NOTCH signaling pathway. 14 1.45E-05 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene. 14 1.53E-05 
Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176]. 14 1.63E-05 
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 12 1.70E-05 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) and long-term adapted for estrogen-independent growth. 14 1.72E-05 
Genes down-regulated during early stages of differentiation of embryoid bodies from J1 
embryonic stem cells. 15 1.85E-05 
Genes up-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of 
KRAS [Gene ID=3845] gene. 13 2.41E-05 
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an 
oncogenic form of KRAS [Gene ID=3845] gene. 17 2.85E-05 
Genes down-regulated during late stages of differentiation of embryoid bodies from J1 
embryonic stem cells. 15 2.91E-05 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene 
ID=648] gene by RNAi. 13 3.02E-05 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL21 [Gene ID=59067]. 15 3.09E-05 
Genes down-regulated in small intestine in PRKCA [Gene ID=5578] knockout mice. 14 3.47E-05 
Genes down-regulated in epithelial lung cancer cell lines over-expressing KRAS [Gene 
ID=3845] gene. 13 3.49E-05 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) and long-term adapted for estrogen-independent growth. 15 3.72E-05 
Genes up-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=] 
stimulation after pre-treatment with the ERK inhibitors U0126 and PD98059 
[PubChem=3006531, 4713]. 13 3.75E-05 
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595] 
gene. 15 3.95E-05 
Genes down-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157]. 15 4.20E-05 
Genes down-regulated during early stages of differentiation of embryoid bodies from V6.5 
embryonic stem cells. 14 4.79E-05 
Genes up-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic 
form of KRAS [Gene ID=3845] gene and knockdown of TBK1 [Gene ID=29110] gene by RNAi. 19 4.94E-05 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable ERBB2 [Gene ID=2064]. 13 5.61E-05 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] 
gene. 13 5.92E-05 
Genes up-regulated in CD34+ hematopoietic progenitor cells after knockdown of RPS14 [Gene 
ID=6208] by RNAi. 13 5.92E-05 
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of RBBP8 [Gene 
ID=RBBP8] gene by RNAi. 11 6.09E-05 
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway 
activation by thyrotropin (TSH). 15 6.69E-05 
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene 
ID=648] gene by RNAi. 11 7.38E-05 
Genes down-regulated in epithelial prostate cancer cell lines over-expressing an oncogenic form 
of KRAS [Gene ID=3845] gene. 11 7.38E-05 
Genes up-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue transgenically 
expressing human AKT1 gene [Gene ID=207]  vs untreated controls. 14 9.93E-05 
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene 
ID=672] gene by RNAi. 12 1.07E-04 
Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717] 
gene by RNAi. 14 1.25E-04 
Genes down-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene 
ID=5728] by RNAi. 12 1.31E-04 
Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 
[Gene ID=648, 7703] genes by RNAi. 12 1.39E-04 
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Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic 
form of KRAS [Gene ID=3845] gene. 18 1.40E-04 
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by 
RNAi. 18 1.40E-04 
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an 
oncogenic form of KRAS [Gene ID=3845] gene. 18 1.46E-04 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable ERBB2 [Gene ID=2064]. 14 1.47E-04 
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] 
gene. 14 1.56E-04 
Genes up-regulated in a panel of epithelial cell lines by TGFB1 [Gene ID=7040]. 14 1.56E-04 
Genes down-regulated in A549 lung carcinoma and M059K glioblastoma cells treated with 
dichloroacetate [PubChem=6597]. 14 1.64E-04 
Genes down-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene. 14 1.64E-04 
Genes up-regulated during early stages of differentiation of embryoid bodies from V6.5 
embryonic stem cells. 13 1.65E-04 
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of 
CCND1 [Gene ID=595] gene. 14 1.73E-04 
Genes up-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157]. 14 1.73E-04 
Genes down-regulated during late stages of differentiation of embryoid bodies from J1 
embryonic stem cells. 12 1.77E-04 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL21 [Gene ID=59067]. 12 1.86E-04 
Genes down-regulated in retina cells from CRX [Gene ID=1406] knockout mice. 10 1.88E-04 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene. 14 1.93E-04 
Genes up-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene ID=7422]. 14 1.93E-04 
Genes up-regulated in retina cells from CRX [Gene ID=1406] knockout mice. 10 2.12E-04 
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595] 
gene. 12 2.27E-04 
Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281]. 12 2.27E-04 
Genes up-regulated in primary thyrocyte cultures in response to cAMP signaling pathway 
activation by thyrotropin (TSH). 14 2.38E-04 
Genes up-regulated in primary epithelial breast cancer cell culture over-expressing E2F3 [Gene 
ID=1871] gene. 12 2.87E-04 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and 
engineered to express ligand-activatable EGFR [Gene ID=1956]. 12 2.87E-04 
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=] 
stimulation. 10 3.01E-04 
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=] 
stimulation after pre-treatment with the ERK inhibitors U0126 and PD98059 
[PubChem=3006531, 4713]. 10 4.41E-04 
Genes up-regulated in granule cell neuron precursors (GCNPs) after stimulation with Shh for 
24h. 11 5.92E-04 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene 
ID=3558] and then stimulated with IL15 [Gene ID=3600]. 11 8.08E-04 
Genes down-regulated in MEF cells (embryonic fibroblasts) with knockout of SNF5 [Gene 
ID=6598] gene. 10 9.29E-04 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene. 11 1.04E-03 
Genes up-regulated in primary thyrocyte cultures in response to cAMP signaling pathway 
activation by thyrotropin (TSH). 11 1.22E-03 
Genes down-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts). 10 1.22E-03 
Genes up-regulated in small intestine in PRKCA [Gene ID=5578] knockout mice. 10 1.22E-03 
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Supp. Table 3.4 Gene Ontology of differentially methylated and differentially expressed 
genes (iAsT v. NT). Gene ontology terms of both hypomethylated (132 genes) and 
hypermethylated (182 genes) genes comparing iAsT to NT. 
 
GO Term Number of Genes p-value 
Hypomethylation (132 Genes) 
Intracellular Signal Transduction 23 3.71E-11 
Intrinsic Component of Plasma Membrane 22 5.89E-10 
Negative Regulation of Cell Death 16 1.99E-09 
Regulation of Cell Death 20 2.88E-09 
Protein Phosphorylation 16 6.10E-09 
Endoplasmic Reticulum 20 1.60E-08 
Homeostatic Process 18 2.22E-08 
Phosphorylation 17 3.80E-08 
Cellular Homeostasis 13 4.15E-08 
Neurogenesis 18 4.54E-08 
Hypermethylation (182 Genes) 
Intracellular Signal Transduction 24 2.22E-09 
Movement of Cell or Subcellular Component 20 3.49E-08 
Kinase Binding 14 4.47E-08 
Cell Development 21 4.51E-08 
Receptor Binding 21 8.03E-08 
Positive Regulation of Molecular Function 23 1.15E-07 
Positive Regulation of Transporter Activity 6 3.35E-07 
System Process 22 4.46E-07 
Tissue Development 20 5.60E-07 
Cell Projection Organization 15 9.68E-07 
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Supp. Table 3.5 Gene Ontology of differentially methylated and differentially expressed 
genes (iAs-rev v. NT). Gene ontology terms of both hypomethylated (67 genes) and 
hypermethylated (141 genes) genes comparing iAs-rev to NT. 
 
GO Term Number of Genes p-value 
Hypomethylation (67 Genes) 
Cell Development 13 5.79E-08 
Intrinsic Component of Plasma Membrane 13 3.06E-07 
Endoplasmic Reticulum 12 1.91E-06 
Neurogenesis 11 2.94E-06 
Neuron Differentiation 9 2.95E-06 
Response to Organic Cyclic Compound 9 4.35E-06 
Ion Transport 10 8.02E-06 
Amide Transport 4 1.01E-05 
Cardiovascular System Development 8 1.22E-05 
Circulatory System Development 8 1.22E-05 
Hypermethylation (141 Genes) 
Intrinsic Component of Plasma Membrane 23 3.50E-10 
Small Molecule Metabolic Process 20 1.71E-07 
Phosphate Containing Compound Metabolic Process 20 9.90E-07 
Cell Junction 15 1.23E-06 
Chemical Homeostasis 13 1.57E-06 
Response to Oxygen Containing Compound 16 2.43E-06 
Homeostatic Process 15 7.51E-06 
Tissue Development 16 7.98E-06 
Heart Development 9 8.86E-06 
Intracellular Signal Transduction 16 1.23E-05 
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Supp. Table 3.6 Gene Ontology of differentially methylated and differentially expressed 
genes (iAs-rev v. iAsT). Gene ontology terms of both hypomethylated (180 genes) and 
hypermethylated (241 genes) genes comparing iAs-rev to iAsT. 
 
GO Term Number of Genes p-value 
Hypomethylation (180 Genes) 
Positive Regulation of Molecular Function 29 4.89E-12 
Intrinsic Component of Plasma Membrane 27 2.28E-11 
Intracellular Signal Transduction 26 4.51E-11 
Signal Transducer Activity 27 6.76E-11 
Cardiovascular System Development 18 3.83E-10 
Circulatory System Development 18 3.83E-10 
Signaling Receptor Activity 23 6.92E-10 
Cell Development 23 1.08E-09 
Receptor Activity 24 3.38E-09 
Positive Regulation of Response to Stimulus 26 3.41E-09 
Hypermethylation (241 Genes) 
Intrinsic Component of Plasma Membrane 41 1.15E-17 
Negative Regulation of Cell Death 24 1.35E-11 
Regulation of Cell Death 30 5.55E-11 
Phosphate Containing Compound Metabolic Process 35 5.61E-11 
Intracellular Signal Transduction 31 5.81E-11 
Response to Oxygen Containing Compound 29 5.95E-11 
Tissue Development 30 1.16E-10 
Movement of Cell or Subcellular Component 27 2.40E-10 
Receptor Binding 29 2.79E-10 
Neurogenesis 28 4.04E-10 
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Supp. Table 3.7 Alternative splicing ANOVA for genes of interest. Alternative splicing 
reads collected for all of the genes investigated for differential gene expression changes 
performed in alternative splicing ANOVA. 
 
Gene Symbol p-value(group) alt-splicing(group) 
CORO1B 0.242728 0.867536 
ARID5B 0.452318 0.985346 
EPC1 0.535415 0.466164 
PPME1 0.593614 0.0578084 
PRDX1 0.825822 0.997596 
DYNC1I2 0.882775 0.934455 
CDH12 0.906168 0.409667 
PPM1L 0.946555 0.338747 
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Supp. Figure 3.1 Distribution of fold change of DNA methylation between groups. 
 
 
(A). Distribution of all hypomethylated CpG sites for iAsT v. NT, iAs-rev v. NT, and iAs-
rev v. iAsT. (B). Distribution of all hypermethylated CpG sites for iAsT v. NT, iAs-rev v. 
NT, and iAs-rev v. iAsT. 
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Supp. Figure 3.2 Scatter plots of CpG methylation reads for hypermethylation and 
hypomethylation within the three data sets. 
 
 
 
(A). iAsT v. NT. (B). iAs-rev v. NT. (C). iAs-rev v. iAsT. 
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Supp. Figure 3.3 Venn Diagrams describing overlaps between differentially methylated 
genes in different treatment groups. 
 
 
 
(A). Venn Diagram of differentially methylated genes for iAsT v. NT (8388 total genes) 
and iAs-rev v. NT (5649 total genes). (B). Venn Diagram of differentially methylated 
genes for iAsT v. NT (8388 total genes) and iAs-rev v. iAsT (10416 total genes). (C). Venn 
Diagram of differentially methylated genes for iAs-rev v. NT (5649 total genes) and iAs-
rev v. iAsT (10416 total genes). Values within each circle identify the subset of methylated 
genes that are unique to that set while the overlap indicates differentially methylated genes 
found in both sets. 
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Supp. Figure 3.4 Venn Diagrams describing DMRs that reversed in methylation status 
after reversal of treatment. 
 
 
 
(A). Venn Diagram depicting genes that were hypomethylated in iAsT cells (4236 total 
genes) and were hypermethylated when comparing iAs-rev v. iAsT (7062 total genes). (B). 
Venn Diagram describing genes that were hypermethylated in iAsT cells (5774 total 
genes) and were hypomethylated when comparing iAs-rev to iAsT (5875 total genes). 
Values within each circle identify the subset of methylated genes that are unique to that 
set while the overlap indicates differentially methylated genes found in both sets. 
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Supp. Figure 3.5 Venn Diagrams describing overlaps between differentially expressed 
genes and differentially methylated genes. 
 
 
 
(A). Venn Diagram of differentially expressed genes (829 total genes) and differentially 
methylated genes in iAsT cells (8388 total genes). (B). Venn Diagram of differentially 
expressed genes (829 total genes) and differentially methylated genes in iAs-rev cells 
(5649 total genes). (C). Venn Diagram of differentially expressed genes (829 total genes) 
and differentially methylated genes between iAs-rev and iAsT (10416 total genes). Values 
within each circle identify the subset of methylated genes that are unique to that set while 
the overlap indicates differentially methylated genes found in both sets. 
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CHAPTER 4. THE EMERGING ROLE OF HISTONE H2B VARIANTS AS 
ONCOHISTONES IN IAS-MEDIATED EPITHELIAL-TO-MESENCHYMAL 
TRANSITION 
 Introduction 
Millions of people around the world are chronically exposed to low levels of 
inorganic arsenic (iAs) through drinking water, food, and occupation3,4,202,203. While 
arsenic can be present in the environment in a variety of forms (organic or inorganic, 
trivalent (3+) or pentavalent (5+)), the inorganic, trivalent state is the most toxic form 
because it is most soluble in water and has a lone electron pair that can participate in bonds. 
Inorganic arsenic can be released into the environment in a variety of ways. Specific 
industries, such as mining and smelting, can release iAs into the ground water and air204,205. 
Furthermore, certain agricultural processes, such as rice farming in China, can incorporate 
iAs into crops if it is present in the soil or water being used to grow plants206,207. Exposure 
to inorganic arsenic is a concern, not only globally, but also within the United States208-210. 
There are many regions within the US where individuals are being exposed to iAs above 
the EPA allowed limit of 10 µg/L (10 ppb)203. Exposure above the EPA limit can occur 
when individuals work in a particular industry or consume crops that have inorganic 
arsenic contaminants. However, the main mechanism of exposure in the US is through 
untreated drinking water203. While the EPA regulates heavy metal contaminants in treated 
drinking water, many people, especially in rural areas, consume drinking water from wells, 
which are untreated sources.  
An example of a region where this is a prevalent problem is Eastern Kentucky, where 
the coal mining industry releases iAs into the ground water. In this region, many people 
use well water as their main source; therefore, their water is not regulated by the EPA and 
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contains low levels of iAs. Beyond that, many people live in this region for decades, so 
they are being exposed to low doses of inorganic arsenic for a long period of time. In 
Eastern Kentucky, cancer rates are higher than normal, specifically lung cancer rates211,212. 
While there are many factors that contribute to the higher cancer rates seen in this area, 
it’s probable that chronic, low dose exposure to inorganic arsenic could be one of those 
contributing factors. 
It has been shown, in lung cancer and in other cancer types, that chronic, low dose 
iAs exposure promotes a specific process that progresses cancer development – the 
epithelial-to-mesenchymal transition (EMT)63,124,213,214. EMT is the process by which 
metastasis can occur in an individual. Through EMT, cells develop the ability to leave the 
original tumor site, move to other regions in the body, and establish new tumors. Many 
cells within our body are categorized as “epithelial” and exhibit cuboidal or spherical 
morphology, adhesion to the surrounding cells and the basement membrane, and polarity 
that allows them to function properly. Because of their adhesive properties, these cells are 
stationary and are not able to travel throughout the body. When these cells go through the 
epithelial-to-mesenchymal transition, they lose their polarity, lose their adhesive 
properties, become elongated and spindle-like, and develop the ability to be mobile215,216. 
This transition gives cells properties that are more indicative of a mesenchymal phenotype. 
In our lab, and in other labs, this process is often studied in BEAS-2B cells, a normal 
lung epithelial cell line. When BEAS-2B cells are treated with a chronic, low dose of 
inorganic arsenic, they go through the epithelial-to-mesenchymal transition, making them 
a good system to study this process. In order to study EMT as a process, our lab developed 
a time course iAs treatment model in BEAS-2B cells to better understand the changes that 
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occur throughout EMT. We begin with nontreated BEAS-2B cells (NT), which represent 
the epithelial phenotype. Then, we treat BEAS-2B cells with a low dose of sodium arsenite 
(0.5 µM) that is similar to levels that individuals would be exposed to in eastern Kentucky, 
or other parts of the United States. Cells were grown with this low dose of iAs and were 
harvested at three weeks (W3), eight weeks (W8), and seventeen weeks (W17). 
Throughout a variety of experiments (wound healing assay, cell migration and invasion 
assays, soft agar assay), our lab confirmed that these three time points reflect early EMT, 
mid EMT, and late EMT, respectively. Then, to bring our cells to a fully transformed state, 
we increased the dose of inorganic arsenic to 2.0 µM on the W17 cells until they had been 
grown for 24 weeks (2.0T). By increasing the dose of iAs at this point, the cells began to 
go through the reverse process – mesenchymal to epithelial transition (MET) – which is 
characteristic of cells that are establishing a tumor in a new region during metastasis. Then, 
we grew the 2.0T cells for another 3-6 weeks in the absence of iAs to identify what changes 
may occur if iAs treatment is reversed. These cells are considered reverse-treated (RT) and 
reflect a case in which someone may be exposed to inorganic arsenic over a long period 
time, but then experience relief from that exposure. 
While several mechanisms have been proposed to explain how iAs exposure 
contributes to the epithelial-to-mesenchymal transition, one of the most prominent is the 
role of epigenetic changes215,216. iAs is unique in that, unlike many other carcinogenic 
agents, it does not cause DNA mutations217. iAs is not a mutagen. Instead, iAs is known 
to cause epigenetic changes, which are changes to the DNA or proteins that compact it. 
Epigenetic changes alter chromatin compaction and gene expression, but do not change 
the DNA sequence. These epigenetic changes can occur either on the DNA itself, or on 
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the proteins which are responsible for compacting the DNA within the nucleus. At the 
most basic level of chromatin compaction, DNA is wrapped about 1.7 times around a 
histone octamer – a cylindrical structure containing two copies of each of the four core 
histone types (H2A, H2B, H3, and H4). Epigenetic changes, such as DNA methylation 
and histone post-translational modifications have been, and are being, well studied in 
response to chronic, low dose iAs treatment30,218. However, a more unique epigenetic 
change, incorporation of histone variants, has garnered less attention. 
Cells produce canonical versions of each of the four main histone types that typically 
get incorporated into most of the nucleosomes within the genome. However, cells also 
produce variants of these histone proteins that can be incorporated into certain genomic 
regions for specific purposes219. For example, histone variants, such as H2AZ.1, H2AZ.2, 
and H3.3, get incorporated into regions where chromatin must be open so that gene 
expression can be active220. Conversely, variants such as mH2A1 and mH2A2 get 
incorporated into regions where chromatin needs to be compacted to prevent gene 
expression91. Histone variants also serve specific purposes in the cell, such as promoting 
developmental processes in early development or signaling regions of DNA damage to 
recruit repair factors221-226.  
Histone variants have been identified for histones H2A, H2B, and H3 and they can 
differ from their canonical counterparts in several different ways219. Some histone variants, 
such as mH2A and H2A.Z, have large regions of amino acid additions or deletions 
compared to the canonical histone. Other histone variants, such as H3.3, have single amino 
acid changes that make them distinct from the canonical histone. Histone variants with 
large amino acid additions and deletions have been well studied because antibody-based 
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techniques can be easily performed by exploiting the large changes in amino acid 
sequence. Investigation of histone variants containing single amino acid changes, on the 
other hand, has not been performed as readily because of the lack of antibodies with 
sufficient specificity. Interestingly, histone variants with single amino acid changes are 
beginning to gain more attention as mutations in histones are being identified and 
implicated in a variety of disease states, especially cancer. In the past few years, 
researchers have identified many mutations that occur in the canonical histone sequence 
that can promote and contribute to cancer development227-229. These histone mutants, 
termed “oncohistones,” get incorporated into the genome and alter chromatin compaction, 
thereby altering gene expression patterns that promote carcinogenesis. While histone 
variants are not mutants, the effect of a single amino acid change in a histone mutant begs 
the question of whether histone variants with point amino acid changes could function as 
oncohistones, as well. 
This question is most relevant for histone H2B variants, which do not exhibit large 
amino acid additions or deletions, but only exhibit a few single changes, spread throughout 
the amino acid sequence (Figure 4.1A). There are sixteen variants of histone H2B and our 
lab identified ten that are dysregulated, both at protein and mRNA levels, in response to 
chronic, low dose exposure to iAs63. Some of these variants, such as H2BH and H2BN, 
only have one amino acid variation in the tail region of the histone protein. Other variants, 
such as H2BK or H2BE, only have one amino acid variation in the core region of the 
histone protein. There are also several histone H2B variants, such as H2BJ or H2BB, that 
have two or three amino acid variations spread throughout the sequence (Figure 4.1A). 
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While the effect of many of the amino acid changes is not yet known, two of the 
amino acid variations can be investigated using PyMol and structures available in the PDB 
(Figure 4.1B). The amino acid variation that occurs at amino acid position 39 is located at 
the interface between histone H2B and the DNA that is wrapped around the octamer. In 
canonical H2B (H2BC), as well as several of the variants, this amino acid is a valine. 
However, in four of the variants, this amino acid position is an isoleucine instead. In 
looking at these amino acid residues within the structure, it appears that an isoleucine at 
this position is able to project closer to the DNA, potentially causing a steric clash that 
would prevent the DNA from wrapping as tightly around the histone octamer (Figure 
4.1C). Furthermore, the amino acid variation that occurs at amino acid position 124 is at 
the interface between histone H2B and histone H2A. In canonical H2B and most of the 
variants, this amino acid is a serine. However, in H2B variants H2BJ and H2BK, this 
amino acid position is an alanine instead. When investigating this amino acid, it’s apparent 
that when serine is present, it forms a hydrogen bond with an adjacent arginine from H2A, 
thereby forming a stabilizing connection between histone H2A and H2B (Figure 4.1D). 
However, when this amino acid is an alanine instead, that hydrogen bond is lost, which 
could alter the interaction between histones H2A and H2B within the histone octamer. 
While structural data suggests the amino acid variations in histone H2B variants could 
cause major changes in nucleosome stability and DNA compaction, no work has yet been 
done to identify the specific impact of histone H2B variants on octamer and nucleosome 
dynamics. Despite this gap in knowledge, dysregulation of histone H2B variants has been 
identified in many cancer types and dysregulation of each of the variants seems to be 
cancer and cell type specific. 
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Using data from cBioPortal, gene expression data for the histone H2B variants was 
extracted for a variety of cancer types. It’s clear from the data that dysregulation of histone 
H2B variant gene expression is cell type and cancer type specific. Dysregulation of histone 
H2B gene expression seems to be most prevalent in breast, bladder, prostate, and uterine 
cancers (Figure 4.2A). Some cancers exhibit mild upregulation or downregulation of the 
histone H2B variant genes while others exhibit severe changes in gene expression of 
several variants (Figure 4.2B). For example, prostate cancer shows significant 
upregulation of HIST1H2BE, HIST1H2BC, HIST2H2BF, and HIST1H2BF. On the other 
hand, low grade glioma (LGG) shows noticeable downregulation of HIST1H2BD, 
HIST1H2BK, and HIST1H2BE. Interestingly, H2B variant genes seem to be particularly 
upregulated in cancers involving reproductive organs such as testicular, cervical, ovarian, 
uterine, and breast. For example, HIST1H2BC is upregulated in prostate and testicular 
cancer while HIST1H2BJ is upregulated in cervical, ovarian, and testicular cancer. It has 
been suggested that iAs drives cancers that involve Hedgehog signaling, such as pancreatic 
and esophageal cancer. Interestingly, both pancreatic and esophageal cancer show 
consistent downregulation of the histone H2B variant genes. Furthermore, inorganic 
arsenic is known to promote squamous cell cancers which include lung squamous cell 
carcinoma, head and neck, and cervical cancer230-234. However, differences in expression 
of the histone H2B variant genes in these types of cancer are moderate. 
The aim of my work has been to understand the role of histone H2B variants, not 
only in the context of iAs-induced carcinogenesis, but also in the context of chromatin 
compaction. Our preliminary data indicated that histone H2B variants are dysregulated in 
response to iAs exposure63. I sought to identify how histone H2B variants are being 
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dysregulated, and the unique role that they may be playing in the epithelial-to-
mesenchymal transition during chronic, low dose iAs treatment. Furthermore, I sought to 
understand how these histone H2B variants could be influencing octamer stability, 
nucleosome stability, and DNA accessibility when they are incorporated into the genome. 
This work has progressed our understanding of histone H2B variants and lays a foundation 
to discern their role not only in disease states, but also in normal cellular functioning. 
 
 Results 
4.2.1 Dysregulation of Histone H2B Expression 
As mentioned previously, earlier studies in the lab had identified that ten histone 
H2B variants were dysregulated both at the gene expression (as measured by quantitative 
real time PCR) and protein levels (as measured by mass spectrometry)63. Each variant 
exhibited unique changes in iAs-induced dysregulation, with some being upregulated and 
others downregulated. However, these initial studies were only performed on cells that had 
been treated with iAs for eight weeks. Therefore, I wanted to evaluate how expression of 
the histone H2B variants changes throughout time course treatment with iAs. Using 
quantitative real time PCR (qRT-PCR), I first identified the expression pattern for 
canonical histone H2BC (Figure 4.3). H2BC exhibited mild expression changes with an 
initial rise in expression at W3 and then a small drop in expression at W8. Then, expression 
steadily increases back toward a more normal level through W17 and 2.0T. Then, 
expression drops slightly once again with reverse treatment. While these trends were 
intriguing, the changes seen with the histone H2B variants were even more interesting. 
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Expression of the histone H2B variants showed similar trends as H2BC, but the 
dysregulation was much more pronounced (Figure 4.3). Expression increased at W3, but 
much more so than the canonical H2B, and expression decreased at W8, but much more 
so than the canonical H2B. Then, as treatment continued in W17 and 2.0T, expression of 
some of the histone H2B variants did not recover back to normal levels, while others 
overshot the normal level and increased drastically. Then, upon reverse treatment, the 
expression of some of the H2B variants was maintained, while the expression of others 
was further increased. These results indicated that the histone H2B variants are, in fact, 
being dysregulated in response to chronic, low dose exposure to iAs. To continue my 
investigation, I wanted to consider what could be causing these iAs-induced expression 
changes.  
 
4.2.2 Dysregulation of Stem Loop Binding Protein 
In order to understand the underlying mechanism of these expression changes, it is 
first essential to understand a unique property of histone mRNA. Most mRNA within the 
cell contains a polyA tail at the 3’ end that is composed of 150-250 adenine nucleotides 
and protects the mRNA from degradation, while also helping its translation efficiency. 
This is helped by the binding of protein factors, such as the polyA binding protein, to the 
polyA tail that facilitate mRNA processing and translation. Histone mRNAs are unlike 
most mRNA within the cell because they do not contain a polyA tail at the 3’ end220. 
Instead, histone mRNA has a 3’ stem loop structure, in which the single stranded mRNA 
folds back and base pairs with itself to form a stem loop structure. Since polyA binding 
protein is not able to bind to this 3’ structure to help the mRNA remain stable and get 
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translated, there is a different protein responsible for that function for histone 
mRNA70,76,220. 
Stem loop binding protein (SLBP) is responsible for binding to the 3’ stem loop and 
stabilizing histone mRNA. It prevents degradation of histone mRNA and promotes 
translation. However, other studies have shown that in response to 24- or 48-hour exposure 
to inorganic arsenic, SLBP levels are depleted70,76. Acute iAs exposure causes reduced 
gene expression for SLBP and increased degradation by the proteasome. Therefore, SLBP 
levels are reduced in response to iAs exposure. However, there have not yet been any 
studies to identify how SLBP levels are dysregulated by chronic exposure to iAs. I used 
qRT-PCR to identify changes in gene expression for the gene that encodes SLBP 
throughout our chronic, low dose iAs treatment model (Figure 4.4A). Upon initial 
treatment with iAs at W3, I saw what I expected – a significant reduction in SLBP mRNA 
levels. However, the trend seen over time was surprising. During treatment through W8 
and W17, it seems that SLBP expression is somehow able to adapt and recover back 
towards normal expression levels. However, once the dose of iAs is increased to 2.0 µM, 
SLBP expression is not able to maintain its recovery and drops back down to about 60% 
of NT mRNA levels. Then, upon reversal of treatment, SLBP expression continues to drop 
to about 25% of NT mRNA levels. I also performed Western Blot to confirm if SLBP 
protein levels exhibit similar changes to gene expression. Although the antibodies 
available on the market for SLBP are not 100% specific, Western Blot showed that protein 
levels of SLBP follow a similar trend to mRNA level changes throughout chronic, iAs 
treatment (Figure 4.4B).  
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4.2.3 Dysregulation of Histone Transcript Polyadenylation 
These results indicated that iAs-induced dysregulation of SLBP is more complicated 
than what is seen in response to acute iAs treatment. SLBP levels undulate throughout 
chronic, low dose exposure to inorganic arsenic. Because of the responsibility of SLBP to 
bind and stabilize histone transcripts, it’s likely that the changes in SLBP levels contribute 
to the changes in histone H2B expression. Interestingly, this story becomes even more 
complicated when considering the relationship between SLBP and histone H2B variant 
mRNA. Unlike canonical histone mRNA, which can only have a stem loop, histone variant 
mRNA can have either a 3’ stem loop or a polyA tail. I hypothesize that at times when 
SLBP is depleted, histone variant transcripts containing a polyA tail could be 
compensating for the loss of canonical histone mRNAs. 
In order to answer that question, I wanted to, once again, perform quantitative real 
time PCR, but only on histone transcripts containing a polyA tail. I performed polyA 
extraction to purify only those transcripts containing a polyA tail, and then analyzed 
expression by qRT-PCR (Supplemental Figure 4.1). I found that each of the 
polyadenylated histone H2B transcripts exhibited a similar trend in expression (Figure 
4.5). Expression of the polyA transcripts drops slightly at W3, increased at W8, drops at 
W17, and then goes back up at W24 and RT. This undulating expression pattern begins to 
make a lot of sense when we combine it with the expression pattern seen for SLBP (Figure 
4.6). 
Upon initial treatment with iAs, SLBP levels drop. Therefore, there is less SLBP 
available to stabilize histone transcripts and they are more likely to be degraded. To make 
up for the loss of canonical histone transcripts, we see a subsequent rise in expression of 
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polyadenylated histone H2B variant transcripts in W8. Then, as SLBP expression adapts 
and recovers back to normal levels in W8 and W17, canonical, stem-looped H2B 
transcripts are able to be stabilized and translated once again. Therefore, there is not a need 
for compensation by polyadenylated H2B variant transcripts, so we see a subsequent drop 
in expression of polyadenylated transcripts at W17. However, when SLBP levels drop 
again upon the increase of the dose of iAs to 2.0 µM, an increase in expression of 
polyadenylated histone H2B variant transcripts is seen again to compensate for the loss of 
stem-looped H2B transcripts. In evaluating these trends, I also identified that not only does 
a rise in expression of polyadenylated transcripts occur at W8 and 2.0T, but polyadenylated 
transcripts also make up a great proportion of total transcripts for each of the histone H2B 
variants (Figure 4.7). 
Based on these trends, it seems that throughout chronic, low dose treatment with iAs, 
SLBP is dysregulated both at the gene expression and protein level. Since SLBP is 
responsible for stabilizing stem-looped histone transcripts, changes in SLBP levels 
throughout iAs treatment cause changes in expression of the histone H2B variants. 
However, histone H2B variants can have either a stem loop or a polyA tail at the 3’ end, 
so polyadenylated histone H2B variants are not as impacted in stability by changes in 
SLBP219,220. It seems that whenever SLBP levels are reduced, expression of 
polyadenylated histone H2B variants rises to compensate for the loss of stem-looped 
canonical histone transcripts. 
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4.2.4 Dysregulation of Histone Transcript Stability 
As suggested earlier, histone transcript stability is disrupted by iAs treatment because 
SLBP, which is responsible for stabilizing histone transcripts with stem-loop structures, is 
dysregulated in response to iAs treatment70,76. However, just like with SLBP levels, this 
has only been studied in response to 24- or 48-hour treatment with inorganic arsenic. To 
identify how histone transcript stability is altered throughout chronic, low dose exposure 
to iAs, steady state levels of histone mRNA were evaluated using qRT-PCR after treating 
cells with actinomycin D, an agent that halts transcription. By evaluating mRNA samples 
at several time points post actinomycin D treatment, a half-life for each histone variant 
transcript could be identified in each iAs treatment group. 
The data indicate that, in general, histone variant transcripts are more resistant to 
degradation than the canonical histone H2BC transcript (Figure 4.8). This is seen in the 
longer half-lives exhibited by the histone variant transcripts (Table 4.1). However, this 
trend is not clear-cut throughout each treatment group. At times throughout iAs treatment, 
such as W3 and 2.0T, the H2BC transcript actually exhibits greater stability than the 
variant transcripts. Therefore, it is likely that stability is of the histone H2BC transcript is 
influenced by the undulating changes in SLBP levels. However, more investigation will 
be needed to confirm these findings and further elucidate how chronic, low dose iAs 
treatment alters histone transcript stability and turnover through changes in SLBP.  
 
4.2.5 Dysregulation of Chromatin Compaction by Histone H2B Variants 
If these histone H2B variants are being dysregulated in response to iAs exposure, 
what effect are they having within the genome when they get incorporated into 
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nucleosomes? In order to answer this question, I used three different techniques – salt 
fractionation, thermal stability assay, and MNase digest. First, I used a salt fractionation 
assay, in which chromatin is extracted from cells and then incubated in increasing 
concentrations of salt buffer. Less compact chromatin is more susceptible to elution in the 
low salt concentration, while more compact chromatin does not elute until it is perturbed 
by a much higher salt concentration235. Using this assay, I have identified that chronic, low 
dose exposure to iAs results in increased global chromatin compaction (Figure 4.9A). 
Furthermore, the use of antibodies in development at ThermoFisher confirmed the 
presence of some histone H2B variants in the most compact chromatin. Antibody 48430 
identified the presence of histone variants H2BJ and H2BK, while antibody 48815 
identified the presence of histone variant H2BB and H2BN (Figure 4.9B and C). It is 
probable that the presence and dysregulation of histone H2B variants could be contributing 
to the global chromatin compaction seen throughout iAs treatment. 
Second, in order to investigate how histone H2B variants influence octamer and 
nucleosome stability, I used a thermal stability assay. The melting temperature of an H2B 
variant-containing octamer or nucleosome was measured at multiple salt concentrations, 
thereby evaluating both temperature and salt stability. For these experiments, I focused on 
evaluating four different histone H2B variants in addition to H2BC (canonical). Several 
factors were considered in deciding to focus my studies on histone variants H2BB, H2BD, 
H2BJ, and H2BK. First, our preliminary mass spectrometry data indicated that H2BJ and 
H2BK were upregulated, while H2BB and H2BD were downregulated63. Furthermore, 
each of these variants exhibit a different combination of the amino acid variations at 
position 39 and position 124 that could be evaluated through PDB structures (Figure 4.1). 
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Therefore, the effect of these histone H2B variants on octamer and nucleosome dynamics 
could be associated to different amino acid variations or combinations of variations. 
To begin, I performed the thermal stability assay on histone octamers containing 
either canonical H2BC or one of the four histone H2B variants. These experiments were 
performed at 0.5M, 1M, 1.5M, and 2M salt (Figure 4.10A-D). Dissociation of the histone 
octamer and nucleosome are sensitive to changes in salt concentration, so I wanted to 
ensure that changes in stability due to the histone H2B variants would be consistent at a 
variety of different salt concentrations. The melting temperature measured for each 
indicates the point at which the melting curve is the steepest as it arrives to its peak. The 
peaks varies for each octamer or nucleosome based on the unique interactions with the 
SYPRO Orange dye as melting occurs. I found that at each salt concentration tested, the 
histone octamer containing histone H2BC melts at a lower temperature that the octamers 
containing a histone H2B variants (Figure 4.11). This suggests that the canonical histone 
octamer is actually less stable than the H2B variant-containing octamers. 
I next performed similar thermal stability assays on nucleosomes containing the 
different histone H2B variants (Figure 4.12A-D). Each nucleosome consisted of a histone 
octamer wrapped by 147 base pairs of the 601 DNA sequence. Nucleosomes exhibit two 
step melting because the H2A-H2B dimer dissociates first, followed by the H3-H4 
tetramer dissociation236. Therefore, two different melting temperatures had to be 
calculated. I found that for the first melting temperature, in which the H2A-H2B dimer is 
dissociating, the trends in melting temperatures correlate to the amino acid variations 
characteristic of each variant (Figure 4.13A). The nucleosome containing H2BD, which 
does not have any variations at amino acid position 39 or 124, is actually more stable that 
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the normal nucleosome, melting at a higher temperature at each salt concentration. The 
nucleosomes containing H2BB, H2BJ, and H2BK are less stable than the normal 
nucleosome, each melting at a lower salt concentration. As expected, the melting 
temperatures for the dissociation of the H3-H4 tetramer did not differ because the H2B 
variants have dissociated and denatured at this point (Figure 4.13B). From these results, it 
seems that when DNA is wrapped around the histone octamer to form a nucleosome, 
variations at amino acid positions 39 and 124 lead to a less stable nucleosome structure. 
Finally, I performed an MNase digest experiment on nucleosomes containing 247 
base pairs of DNA wrapped around a histone octamer containing one of the histone H2B 
variants. In this experiment, I was able to determine if the accessibility of DNA to MNase 
is influenced by the presence of a histone H2B variant. I found that DNA is less accessible 
to MNase when one of the histone H2B variants is incorporated into the nucleosome 
(Figure 4.14). DNA wrapped around the wild type histone octamer is much more sensitive 
to MNase digestion than the DNA wrapped around H2B variant-containing histone 
octamers. 
 
 Discussion 
The work presented here showcases the potential role of histone H2B variants in 
inorganic arsenic-mediated cancer development. Throughout the epithelial-to-
mesenchymal transition, not only does expression of histone H2B variants change, but the 
RNA processing that occurs at the 3’ end of histone variant transcripts changes as well. 
H2B variants with a polyA tail are present in a greater amount to compensate for the loss 
of SLBP, and subsequent reduction in stabilization of canonical, stem-looped H2B 
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transcripts. Since the polyadenylated histone H2B variant transcripts are more stable and 
persist longer in the cell, it’s plausible that they could be incorporating into the chromatin 
in inordinate amounts, thereby disrupting normal gene expression patterns70,76. 
My biophysical experiments indicated that, in general, the incorporation of a histone 
H2B variant into an octamer or nucleosome leads to a more stable structure (Figure 4.11 
and 4.12). Not only do histone octamers exhibit greater stability when an H2B variant is 
present, but the DNA is less accessible as well (Figure 4.14). It’s clear that histone H2B 
variants influence octamer and nucleosome dynamics and could alter compaction, 
accessibility, and chromatin compaction wherever they are incorporated. 
My work is consistent with our previously published data that highlighted the novel 
finding that histone H2B variants exhibit changes in response to low dose, iAs exposure 
at both the mRNA and protein level63. This study expanded that previous investigation by 
identifying changes to H2B expression over a longer period of time and at multiple time 
points. Through this more expansive study, I was able to more intricately identify changes 
in H2B variant expression throughout the process of the epithelial-to-mesenchymal 
transition (Figure 4.3). It is evident that disruption of SLBP levels drives the pattern of 
H2B variant expression seen throughout chronic treatment with iAs (Figure 4.4). My work 
agrees with previously published data that indicates reduction of SLBP levels in response 
to 24- or 48-hour exposure to inorganic arsenic70,76. However, treatment with iAs for a 
longer period of time reveals more complex changes in SLBP expression and protein 
levels.  
The next logical step for this investigation would be to perform ChIP-Seq for the 
histone H2B variants to determine the regions within the genome in which they are 
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incorporated under normal conditions and iAs treatment conditions. Unfortunately, since 
the histone H2B variants have only a few amino acid variations that are spread throughout 
the protein, it has been difficult to develop antibodies that are specific to just one histone 
H2B variant. In collaboration with ThermoFisher Scientific, we have contributed to 
development of histone H2B variant antibodies; however, most of the antibodies exhibit 
specificity to multiple histone H2B variants, preventing them from being useful for 
Western Blot, much less ChIP-Seq experiments. In the current study, I was able to identify 
changes to gene expression for each of the ten histone H2B variants, but I was not able to 
correlate those gene expression changes to protein levels for each of the variants since 
Western Blot could not be performed successfully. I hope that, eventually, effective 
antibodies will be developed so that the sites of genomic incorporation for the histone H2B 
variants can be identified. I conjecture that in response to iAs exposure, the histone H2B 
variants are being incorporated into the genome more than they should and are causing 
disruption in gene expression that is promoting carcinogenesis in our cells.  
Until successful H2B variant antibodies are created, there are two available options 
for delineating their incorporation into the genome. First, the currently available antibodies 
could be used to perform ChIP-Seq. While these antibodies can’t distinguish between 
individual histone variants, they can distinguish variants from canonical H2B. Therefore, 
an experiment of this sort could provide insight on the genomic locations where histone 
H2B variants, in general, are being incorporated. The other option is to create tagged 
histone H2B variants and introduce them into cells. While this would allow for more 
precise identification of genomic incorporation, it’s possible that these tagged histone H2B 
variants may not be incorporated into the genome in the same locations that they would if 
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they were being produced under normal conditions. I imagine that a combination of both 
of these methods will be necessary to determine regions of genomic incorporation for the 
histone H2B variants. 
Beyond iAs-induced changes in expression, this work also indicated that the 
incorporation of histone H2B variants into an octamer or nucleosome can disrupt normal 
stability, compaction, and accessibility. This is consistent with the extensive data 
characterizing the effect that histone H2A or H3 variants have on the nucleosome91,237,238. 
However, this work is novel in that it is the first time that the histone H2B variants have 
been investigated for their biophysical properties. While the structural effects of H2A and 
H3 variants are more pronounced because of the large amino acid additions and deletions 
present in those histone variants, our work suggests that the small point amino acid changes 
found in the histone H2B variants can also influence nucleosome dynamics. This finding 
is consistent with the current research being done on the role of mutant histones 
(oncohistones) in cancer development227-229. A single amino acid mutation in a histone 
protein can drive cancer progression; therefore, it is reasonable to believe that a single 
amino acid change found in a histone variant could function similarly, if employed in the 
wrong place at the wrong time. 
This work provides unique insight for the emerging “oncohistone” field, which is 
currently focused on histone mutations. While the histone H2B variants are not mutants, 
they exhibit similar single amino acid changes compared to the canonical histone protein. 
Therefore, histone mutants and histone variants could both be functioning similarly as 
oncohistones. The work that is being done on histone mutants can and will inform the 
investigatory path forward for understanding the role of histone H2B variants in disease 
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states, such as iAs-induced cancer development. Conversely, the work done with histone 
H2B variants and other histone variants will complement and reinforce the research being 
done on histone mutants. 
Because of the current lack of successful antibodies, histone H2B variants have been 
the least studied histone variant. While much research has shown the influence of H2A 
and H3 variants in normal functioning, as well as disease states, there is still a lot of work 
that needs to be done to understand the function of histone H2B variants. Before we can 
characterize the impact of histone H2B variants in a disease state, we first must understand 
their role in normal cellular functioning. While the current study began investigating 
histone H2B variants biophysically, further studies are needed to elucidate how histone 
H2B variants influence DNA target site accessibility, nucleosome remodeling, and 
nucleosome stability.  
This study is the first not only to characterize histone H2B variants in a disease state, 
but also to begin to understand their role in normal nucleosomal functioning. Histone H2B 
variants create a more compact octamer and nucleosome structure and reduce DNA 
accessibility. In response to chronic, low dose iAs exposure, H2B variants exhibit an 
undulating expression pattern that is brought upon by an undulating pattern in SLBP levels. 
Expression of polyadenylated histone H2B transcripts responds to changes in SLBP levels 
in order to adapt and compensate for the reduced stability of canonical histone H2B 
transcripts. The dysregulation of histone H2B variants by SLBP most likely alters gene 
expression patterns that promote the epithelial-to-mesenchymal transition observed in 
response to chronic, low dose iAs treatment. 
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Table 4.1 Half-lives of histone H2B transcripts in response to actinomycin D treatment. 
 
 Histone H2B Transcript – Half Life 
Treatment 
Group 
C B D J K H 
NT 30.40 15.10 23.49 111.80 92.82 43.99 
W3 84.20 53.72 62.05 80.54 81.32 58.03 
W8 76.87 107.00 72.28 65.67 75.86 89.20 
W17 40.92 30.73 42.20 71.92 72.13 57.62 
2.0T 200.10 22863.00 93.54 71.18 99.05 66.59 
RT 104.10 99.67 132.10 170.10 215.20 105.50 
 Histone H2B Transcript – 95% Confidence Interval for Half Life 
Treatment 
Group 
C B D J K H 
NT 23.04 to 
40.57 
8.342 to 
23.53 
15.83 to 
34.72 
53.85 to 
327.0 
63.70 to 
142.8 
29.76 to 
66.52 
W3 67.69 to 
106.4 
42.79 to 
68.30 
52.91 to 
73.21 
75.16 to 
86.42 
68.99 to 
96.76 
50.05 to 
67.66 
W8 61.52 to 
97.55 
61.75 to 
225.6 
57.41 to 
92.49 
55.52 to 
78.30 
69.61 to 
82.89 
64.38 to 
128.4 
W17 36.62 to 
46.05 
23.47 to 
41.44 
30.36 to 
62.82 
57.93 to 
90.17 
63.32 to 
82.45 
45.12 to 
75.35 
2.0T 46.09 to 
??? 
94.89 to 
??? 
46.92 to 
1780 
50.50 to 
117.8 
49.45 to 
2530 
32.76 to 
1119 
RT 66.15 to 
170.6 
69.70 to 
147.0 
80.25 to 
242.5 
99.88 to 
341.0 
105.3 to 
740.7 
72.91 to 
158.0 
 
Histone variant transcript stability was measured using qRT-PCR after actinomycin 
treatment for multiple time points. Relative amounts of transcripts were graphed and half-
life was measured (in minutes) for each transcript in each treatment group. Half-life was 
measured using non-linear one-phase decay function. 
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Figure 4.1 Histone H2B variants exhibit small amino acid changes - some of which are 
present at histone:DNA or histone:histone interfaces. 
 
 
 
(A). Diagram showing amino acid variations (boxed in black) in the ten histone H2B 
variants identified in our study as being differential expressed in response to chronic, 
inorganic arsenic treatment. (B). Nucleosome structure with amino acid variant positions 
39 and 124 in histone H2B pointed out in red. (C). Amino acid variation at position 39 on 
histone H2B with canonical valine in green and variant isoleucine overlayed in turquoise. 
(D). Amino acid variation at position 124 on histone H2B with canonical serine in green 
and variant alanine overlayed in turquoise. 
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Figure 4.2 Dysregulation of H2B variant expression is cancer and cell type specific. 
 
 
 
(A). Bar graph depicting incidences of histone H2B mutations in different cancer types, as 
identified by cBioPortal. (B). Heat map depicting expression changes of histone H2B 
variant genes in a variety of cancer types, as identified by the Cancer Genome Atlas. 
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Figure 4.3 Chronic, low dose exposure to iAs disrupts expression of histone H2B variant 
transcripts. 
 
 
 
 
The ten histone H2B genes, measured by qRT-PCR, exhibited changes in total expression 
over the course of chronic, low dose iAs exposure. Most variants shared a similar pattern 
with increased expression upon initial treatment and a large drop in expression after eight 
weeks of treatment. Then, expression levels rose back towards the nontreated level with 
further treatment. 
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Figure 4.4 iAs exposure disrupts expression of stem loop binding protein (SLBP). 
 
 
 
(A). Gene expression changes of gene encoding SLBP throughout chronic, low dose 
exposure to inorganic arsenic, as measured by quantitative real time PCR. (B). Western 
Blot depicting changes in protein level of SLBP throughout iAs treatment. Central band is 
SLBP. Top band is phosphorylated SLBP and bottom band is non-specific binding. TBP 
was used as control. 
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Figure 4.5 Expression of polyadenylated histone H2B variant transcripts follow an 
undulating pattern throughout iAs treatment. 
 
 
 
Histone H2B mRNA transcripts containing a polyA tail were measured using quantitative 
real time PCR. Polyadenylated transcripts increase in expression at W8, 2.0T and RT. 
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Figure 4.6 Expression of histone H2B variant polyA expression correlates to changes in 
SLBP expression. 
 
 
 
This graph depicts expression of SLBP and general expression trend of the polyadenylated 
histone H2B variants, as determined by quantitative real time PCR. Increases in expression 
of polyadenylated histone H2B variants follows drops in SLBP expression, while 
decreases in expression of polyadenylated histone H2B variants follows increases in SLBP 
expression. 
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Figure 4.7 PolyA transcripts comprise a greater ratio of total H2B variant expression 
during iAs exposure. 
 
 
 
Graph depicting ratio of relative expression of polyadenylated transcripts to total 
transcripts for histone H2B variants. Polyadenylated transcripts comprise a greater ratio of 
total expression for each variant at week 8 and 2.0T. 
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Figure 4.8 Histone H2B variant transcripts exhibit differential stability throughout 
chronic, low dose iAs treatment. 
 
 
 
Transcript levels for histone H2B C, B, D, J, K, and H were measure via qRT-PCR at 
multiple points for each of the six treatment groups. qRT-PCR data presented as mean ± 
SEM of half-life through 3 technical replicates. Data was fit to a non-linear one-phase 
decay function to determine half-life. Variants display various patterns of stability 
throughout iAs treatment. 
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Figure 4.9 iAs treatment causes global chromatin compaction. 
 
 
(A). Salt fractionation was used to determine compaction of chromatin throughout iAs 
treatment. Chromatin compaction increases as iAs treatment progresses. (B). Western Blot 
of resuspended precipitates for each salt fraction with trial antibody from Thermo Fisher 
that binds to H2B variants J and K. (C). Western Blot of salt fractions with trial antibody 
from Thermo Fisher that binds to H2B variant B. 
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Figure 4.10 Histone H2B variant-containing octamers exhibit differential stability at a 
variety of salt concentrations. 
 
 
 
(A). Thermal stability assay of histone H2B variant-containing octamers at 0.5M NaCl. 
(B). Thermal stability assay of histone H2B variant-containing octamers at 1M NaCl. 
(C). Thermal stability assay of histone H2B variant-containing octamers at 1.5M NaCl. 
(D). Thermal stability assay of histone H2B variant-containing octamers at 2M NaCl 
 
  
122 
 
Figure 4.11 Wildtype histone octamer is less stable than H2B variant-containing histone 
octamers. 
 
 
 
Wildtype histone octamer melts at a lower temperature than all of the H2B-variant 
containing octamers at each salt concentration. WT melting temperature is significantly 
different than variant melting temperatures at 0.5, 1.0, and 1.5M salt concentrations. 
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Figure 4.12 Histone H2B variant-containing nucleosomes exhibit two-step melting and 
differential stability at a variety of salt concentrations. 
 
 
 
(A). Thermal stability assay of histone H2B variant-containing nucleosomes at 0.5M NaCl.  
(B). Thermal stability assay of histone H2B variant-containing nucleosomes at 1M NaCl.  
(C). Thermal stability assay of histone H2B variant-containing nucleosomes at 1.5M NaCl.  
(D). Thermal stability assay of histone H2B variant-containing nucleosomes at 2M NaCl 
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Figure 4.13 Histone H2B variant-containing nucleosomes exhibit variation in stability 
that corresponds to the amino acid changes found in each variant. 
 
 
Nucleosomes exhibit two stage melting with the first stage (A) being the release of the 
H2A-H2B dimers and the second stage (B) being the release of the H3-H4 tetramer236. 
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Figure 4.14 Histone H2B variant-containing nucleosomes exhibit different DNA 
accessibility to MNase digestion. 
 
 
 
(A). MNase digestion of 247 bp 601 DNA wrapped around histone octamer containing 
one of the histone H2B variants. Top row of bands is reconstituted nucleosome and lower 
bands are subnucleosomal particles created by digestion239. (B). Graph of loss of 
reconstituted nucleosome as measured by top row of bands for each time point using 
function y=m1*(exp(-m2*m0). 
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Supp. Figure 4.1 Transcripts containing polyA tail are successfully purified from non-
polyadenylated transcripts by polyA extraction. 
 
 
 
Quantitative real time PCR was used to verify purification of polyA transcripts using 
Promega PolyATtract® mRNA Isolation System. RPPH1 is transcript that does not 
contain polyA tail. 
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CHAPTER 5. CONCLUSIONS 
 iAs Promotes the Epithelial to Mesenchymal Transition 
Throughout the world and in the United States, numerous individuals are exposed to 
low levels of inorganic arsenic through drinking water, occupation, or contaminated food 
sources1,4,217. While exposure, oftentimes, does not occur above 1 µM, chronic exposure 
to low levels of iAs can contribute to the development of several disease states156,157,240,241. 
Numerous studies have linked iAs exposure to cardiovascular disease, diabetes, and 
cancer156,157,240. Regions in which iAs exposure is common exhibit higher incidences in 
many cancer types, including lung, prostate, and bladder cancer157,241-244. It has been shown 
that iAs contributes to cancer development by promoting a specific carcinogenic process 
– the epithelial-to-mesenchymal transition25,124,214,245. This process is responsible for 
metastasis, in which tumor cells can leave their site of origin and establish new tumors in 
other locations throughout the body215,216,246. During EMT, cells change in morphology 
and lose their adhesive properties so that they can become mobile. Then, once cells begin 
forming a new tumor in another location, they revert back to an epithelial phenotype, 
through the process of MET. 
Several mechanisms have been identified for how iAs progresses EMT and cancer 
development. For example, chronic, low dose iAs exposure is known to increase oxidative 
stress, reduce DNA repair, and lead to large chromosomal aberrations13,247-249. 
Interestingly, iAs is not mutagenic. Instead, iAs causes a variety of changes to the 
epigenome, which alter chromatin compaction and gene expression patterns to promote 
carcinogenesis39,214,250. While iAs has been shown to influence epigenetic regulators such 
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as histone PTMs, alternative splicing, and microRNAs, this study focused on the influence 
of iAs on DNA methylation and histone variants. 
 
 iAs Disrupts DNA Methylation Patterns 
Numerous studies have shown changes in global DNA methylation in response to 
iAs25,31,39,213,218. However, our understanding of these changes has been limited because 
the analysis was low resolution and methylation patterns varied by cell type and cancer 
type. It is essential to use high resolution studies to identify changes in DNA methylation 
patterns at specific genes and gene regions to more clearly elucidate how iAs modulates 
this epigenetic mark to promote carcinogenesis. While hypermethylation may be observed 
in some regions of the genome in response to iAs, hypomethylation may be observed in 
other regions. Furthermore, methylation can cause either repression or activation of gene 
expression based on the region where it is found. Therefore, high resolution studies are 
more effective at identifying the unique iAs-mediated DNA methylation changes that are 
occurring throughout the genome and how they are intricately altering gene expression 
patterns to promote carcinogenesis. 
My investigation in HeLa cells revealed that over 30,000 CpG sites are differentially 
methylated in response to iAs exposure, with some being hypomethylated and others 
hypermethylated. This differential methylation is concentrated at CpG islands, upstream 
promoter regions, and gene bodies, which suggests functional implications for these iAs-
induced changes. Particularly, gene ontology analysis revealed that methylation changes 
occur at many genes involved with cell signaling, development, and metabolism. 
Furthermore, this study revealed that some DNA methylation changes are transient and 
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revert back to normal after iAs is removed, while others are more permanent and persist 
even when the iAs is no longer present. This correlates to the moderate reversal of EMT 
observed in cells that undergo reversal of iAs treatment and suggests that methylation 
patterns may promote gene expression patterns that drive EMT. 
My data revealed that many of the DNA methylation changes identified by 
microarray analysis correlated to changes in gene expression. However, due to the vast 
presence of hyper- and hypo-methylation, it’s plausible that not all CpG sites are 
responsible for regulating transcription. Methylation at CpG may lead to other changes, 
such as alterations in the presence of nearby epigenetic marks or the binding of regulatory 
factors. More work will be needed to determine the various effects of hyper- and hypo-
methylation at specific genic regions in response to iAs. While profiling studies such as 
these provide a large amount of information, it is imperative that future studies are done 
to complement existing data and provide a more detailed analysis of the functional 
consequences of the methylation changes.  
As work continues in the field, it will be exciting to discover how DNA methylation 
influences and interacts with other epigenetic marks, such as histone post-translational 
modifications (PTMs). DNA methylation is already known to be coregulated with 
H3K27me3, but I imagine that there is crosstalk with many other histone PTMs, as 
well200,201. Histone PTMs can permit, increase, or restrict access to chromatin by 
transcription factors and other regulators. It is probable that DNA methylation can and 
does work in concert with histone PTMs to influence chromatin compaction and DNA 
accessibility. Crosstalk between different epigenetic factors could be determined using 
chromatin immunoprecipitation, by which the presence of multiple epigenetic factors can 
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be identified in a specific genomic location. Furthermore, biophysical techniques could be 
used to measure the combinatorial effects of multiple epigenetic marks present in a single 
nucleosome. I expect that both of these strategies will be necessary to expand our 
understanding of epigenetic crosstalk. Beyond that, more investigation is necessary to 
determine how the “writers, readers, and erasers” of DNA methylation are connected to 
and influenced by the DNA methylation changes identified in this study. Our lab has 
identified that iAs-induced disruption of CTCF and DNMTs underlies many of the DNA 
methylation changes observed in response to iAs exposure213,251. While this hints at a 
particular mechanism, no one has yet determined how these DNA methylation changes 
alter the binding of regulatory factors or transcription factors to hyper- or hypo-methylated 
genomic regions. 
 
 iAs Alters Histone H2B Variant Levels 
iAs is known to cause changes in expression, protein levels, and nucleosome 
incorporation of several histone variants including H3.3, H2A.Z, and H2A.X70,76,252-254. 
When these histone variants get integrated in the wrong locations at the wrong time, they 
can disrupt normal gene expression patterns and contribute to iAs-induced 
carcinogenesis63,227.  Unfortunately, there is a large gap in the field regarding the role of 
histone H2B variants in iAs-induced carcinogenesis. My studies revealed that histone H2B 
variant transcripts are dysregulated at the transcript level in response to chronic, low dose 
iAs exposure. This is due, in part, to disruption of SLBP levels which occurs because iAs 
causes reduced expression and increased degradation of SLBP70,76. In response to chronic 
iAs exposure, SLBP levels undulate and the expression of histone H2B variants responds. 
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Whenever SLBP levels are reduced, expression of polyadenylated histone H2B transcripts 
is increased to compensate for the loss of stability for stem looped histone H2B transcripts. 
Upregulation of the histone H2B variants seems to contribute to a more compact chromatin 
state, which is seen throughout chronic iAs treatment. My studies revealed that 
incorporating histone H2B variants into a histone octamer or nucleosome alters 
nucleosomal properties, such as stability and DNA accessibility. Since little work has been 
done to investigate histone H2B variants, more investigation is necessary to elucidate their 
role not only in iAs treatment conditions, but also in normal cellular functioning. Our lab 
will continue to study histone H2B variants in the coming years, as outlined in the 
following “Future Directions” section. 
 
 Future Directions 
As this study continues in the Fondufe-Mittendorf lab, there are multiple avenues for 
further investigation. Due to the lack of antibodies for the histone H2B variants, the focus 
has shifted from in vitro assays to biophysical assays. While the thermal stability assays 
and MNase digestion highlighted in my work provide details about the influence of histone 
H2B variants on nucleosome structure, nucleosomes are dynamic entities and there are 
multiple facets of their functioning that must be studied239.  
In order to study the biophysical properties of histone H2B variant-containing 
nucleosomes, the lab has been developing the capability to perform Fluorescence 
Resonance Energy Transfer (FRET). FRET relies on the detection of distance between two 
fluorophores based on the transfer of fluorescent energy from one fluorophore to another. 
The emission spectra of the donor fluorophore (Cy3) overlaps with the excitation spectra 
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of the acceptor fluorophore (Cy5) (Figure 5.1A). Therefore, when Cy3 is excited, it will 
release an emission that will excite Cy5. When Cy5 gets excited by Cy3, its emission is 
proportional to the distance between the two fluorophores. FRET is able to measure the 
distance between two labeled entities by measuring differences in fluorescence between 
the two fluorophores. 
For the purpose of our experiments, a Cy3 end-labeled 601 DNA strand is wrapped 
around a Cy5 labeled histone octamer containing one of the histone H2B variants (Figure 
5.1B). FRET can be used to measure compaction of DNA around the histone octamer and 
the amount of DNA unwrapping and breathing that is occurring255-257. FRET should be a 
successful tool to measure changes in DNA breathing because, in our system, Cy3 and 
Cy5 will be 2-6 nm apart which is within the 6 nm optimal distance for those fluorophores. 
I anticipate that the FRET studies will show similar changes in nucleosome dynamics as 
the thermal stability assay. However, FRET can be used to elucidate changes in 
nucleosome dynamics beyond just breathing. 
Our FRET system can be modified so that we can also use this technique to measure 
DNA target site accessibility. In this case, a 601 DNA sequence with an engineered LexA 
binding site will be wrapped around a histone octamer containing one of the four histone 
H2B variants (Figure 5.1C)255,256. LexA, a DNA binding protein, will be titrated in to bind 
to its target site. When LexA binds to its binding site on the DNA, it will destabilize the 
interaction between the DNA and histone octamer, opening up the nucleosome and 
decreasing FRET efficiency. The effectiveness of the LexA binding and its ability to 
disrupt the FRET efficiency will indicate how accessible the DNA target is with different 
histone H2B variants incorporated into the nucleosome. I hypothesize that the 
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incorporation of these histone variants into the nucleosome system will have an impact on 
the FRET efficiency and target site accessibility. For example, variants B and J, which 
have the V39I amino acid change, are predicted to facilitate greater DNA accessibility 
because of the way the isoleucine probes the DNA away from the histone. This experiment 
will define the functional role of each histone H2B variant with regards to DNA target site 
accessibility.  
Beyond FRET experiments, this study can also be expanded with the use of 
experiments utilizing radiolabeled DNA, similar to the MNase digest experiments shown 
in Chapter 4239. One such experiment would involve digesting DNA with DNAse I instead 
of MNase. This would allow for a more extensive identification of regions of DNA that 
are more or less accessible to digestion when wrapped around octamers containing 
different H2B variants (Figure 5.2A). For example, could histone H2B variants promote 
more DNA accessibility at the nucleosome dyad versus the entry/exit regions? By titrating 
DNase I into nucleosome assemblies and running DNA digestion products on a sequencing 
gel, DNase I digestion patterns can be elucidated in the context of histone H2B variant 
incorporation. 
Similarly, radiolabeled DNA containing an engineered enzyme restriction site can be 
wrapped around H2B variant-containing octamers to determine target site accessibility 
(Figure 5.2B)239. By placing the restriction sites at different locations within the DNA 
sequence, accessibility of different portions of the DNA can be determined in the presence 
of histone H2B variants. Furthermore, this technique can also be used to evaluate 
nucleosome sliding and remodeling. A remodeler, such as RSC or Nap1, can be introduced 
so that the enzyme restriction site is buried within the nucleosome if remodeling or sliding 
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occurs. Digestion patterns will then reveal the extent of nucleosome sliding and 
remodeling when histone H2B variants are incorporated into the nucleosome. 
Although antibody-based techniques are not yet possible for studying histone H2B 
variants, the continuation of this project may explore the use of tagged histones. We are 
currently collaborating with the lab of Dr. Jonathan Licht (University of Florida) to 
develop HA-tagged histone H2B variants that we can introduce into our BEAS-2B cells258. 
By introducing these tagged histone H2B variants into our cellular model, we may be able 
to gain insight on the specific regions within the genome where these histone H2B variants 
are being incorporated, both under normal conditions and in response to chronic, low dose 
inorganic arsenic exposure. Furthermore, by overexpressing one or more of the histone 
H2B variants, we may be able to identify specific cellular changes that are instigated by 
these histone variants. It’s plausible that overexpression of the histone H2B variants could 
promote EMT, since several of them are upregulated in iAs-mediated carcinogenesis and 
a variety of other disease states.  
In combination, these studies will move the field forward in understanding the effect 
of histone H2B variants on nucleosome dynamics and iAs-induced carcinogenesis. 
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Figure 5.1 Fluorescence Resonance Energy Transfer (FRET) can be used to further 
investigate nucleosome dynamics. 
 
 
(A). Schematic of FRET system. Green dot is donor fluorophore label (Cy3) and red dot 
is acceptor fluorophore label (Cy5). (B). Schematic of FRET system for determining DNA 
wrapping/unwrapping. (C). Schematic of FRET system for determining DNA target site 
accessibility. 
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Figure 5.2 Radiolabeled DNA can be used to study the influence of histone H2B variants 
on nucleosome dynamics. 
 
 
(A). Schematic of nucleosome design for DNase digest experiments to investigate the 
influence of histone H2B variants on DNA accessibility. (B). Schematic of nucleosome 
design to investigate the influence of histone H2B variant on nucleosome sliding and 
remodeling. 
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